

**Curriculum Vitae:**

**William Philip Werschler - MD, FAAD, FAACS**

**Office Address**

324 South Sherman Street      Phone: (509) 624-1184  
Spokane, WA. 99202              Fax: (509) 625-1449  
Email: pkwerschle@aol.com

**Education**

1981 - 1985                      MD, Graduation Honors  
George Washington University Medical Center  
Washington, DC  
1976 - 1981                      BA, BS, Magna Cum Laude  
Eastern Washington University  
Cheney, WA

**Post Graduate Education**

1997                              Physician Entrepreneur Program  
Kellogg Graduate School of Management  
Northwestern University  
Evanston, IL  
1988 - 1989                      Chief Resident, Dermatology  
George Washington University Medical Center  
Washington, DC  
1986 - 1988                      Resident, Dermatology  
George Washington University Medical Center  
Washington, DC  
1985 - 1986                      Internship, Internal Medicine  
University of Arizona  
Tucson, AZ

### **Academic Appointments**

2021 – Present Clinical Professor of Dermatology, WSU Elson S. Floyd College of Medicine

1992 – Present Associate Clinical Professor in Medicine/Dermatology, University of Washington

1989 – 1992 Clinical Instructor in Medicine/Dermatology, University of Washington

1986 – 1989 Clinical Instructor  
George Washington School of Medicine  
Washington, DC

### **Professional Experience**

2005 – Present ***Clinical Research, Premier Clinical Research  
Principal Investigator***  
324 South Sherman Street, Suite A2, Spokane, WA 99202

1992 – 2005 ***Clinical Research, Spokane Dermatology Clinic***  
324 South Sherman Street, Suite A2, Spokane, WA 99202

1989 – Present ***Private Practice, Spokane Dermatology Clinic***  
324 South Sherman Street, Suite A1, Spokane, WA 99202

1987 – 1989 Consultant, HMO  
George Washington University Health Plan Washington, DC

### **Certification**

Diplomat, National Board of Medical Examiners  
Board Certified, American Board of Dermatology  
Fellow, American Academy of Dermatology  
Fellow, American Academy of Cosmetic Surgery  
Fellow, American Society for Dermatologic Surgery  
Basic Life Support  
Advanced Cardiac Life Support

## **Licensure**

Washington, MD00026292

Hawaii, MD 13631

New York, 238324

Arizona, 34865

California, G87651

Nevada, 11969

Washington DC, MD036622

Idaho, M-9860

Colorado, 45897

Illinois, 036.121527

Michigan, 4301093194

## **Honors**

- 2004 Model State Award presented to Washington State Dermatology Association by American Academy of Dermatology Association, (Wm. Philip Werschler President of Washington State Dermatology Association).
- 2002 – 2006 Best Doctors in America
- 2001 Alumnus Service Award, EWU Alumni Association
- 1985 Walter F. Rosenburg Award in Dermatology,  
George Washington University Medical School  
Graduation Honors
- 1985 Kane King Honor Society,  
George Washington University Medical School  
Graduation Award
- 1982 – 1993 Levine Foundation Scholarship  
George Washington University Medical School
- 1981 Magna Cum Laude Graduation Honors  
Eastern Washington University
- 1981 US Jaycees Outstanding Young Men of America Award

## **Organizational Leadership**

1990 – 1992	Eastern Washington University College of Science, Math and Technology Advisory Committee
1992 – Present	Leaders Society, Dermatology Foundation; State Chairman '94-96
1993 – 1999	Eastern Washington University Foundation Board of Directors
1997 – 1999	Washington State Medical Association, Board of Trustees
1996	President, Spokane County Medical Society
1996 – 2000	Spokane Momentum Economic Development Council
1997 – 1998	United Way of Spokane County, Board of Directors
1995 – 1996	American Cancer Society, Spokane Chapter President
1992	Leadership Spokane Graduate
1993 – 1995	Leadership Spokane, Board of Directors
1998 – 2004	Dermatology Medical Director, Dermik Laboratories
2003	Lifetime Member, Annenberg Circle & Leaders Society, Dermatology Foundation
2003 – 2004	President, American Society of Cosmetic Dermatology & Aesthetic Surgery (ASCDAS)
2001 – Present	Board of Directors, ASCDAS
2004 – 2005	President, Washington State Dermatology Association
2005	Lifetime Founding Member, Amonette Circle, Skin Cancer Foundation
2005 – 2006	International Society on Cosmetic and Laser Surgery, Board of Trustees
2008 – 2009	President, American Society of Cosmetic Dermatology & Aesthetic Surgery (ASCDAS)
2015 – Present	Chair – Aesthetic + Medical Symposium
2016 - 2018	AACS Board Member
2018	AACS Foundation Board President
2018 - Present	Dominion Aesthetic Technologies, Inc.

**Professional Organizations**

Fellow, American Academy of Dermatology

Fellow, American Academy of Cosmetic Surgery

Fellow, American Society of Dermatologic Surgery

Fellow, American Society of Mohs Surgery

Fellow, Past President, American Society of Cosmetic Dermatology & Aesthetic Surgery

Fellow, International Society of Dermatology Surgery

Member, American Academy of Anti-Aging Medicine

Member, American Society of Laser Medicine and Surgery

Member, Washington State Medical Society

Member, Past President, Washington State Dermatology Association

Member, Past President, Spokane County Medical Society

Member (Past), Judicial Council, Washington State Medical Association

## **Clinical Research**

Conducts the following studies with trained and experienced full-time in-office Clinical Research Coordinators in association with Spokane Dermatology Clinic and Premier Clinical Research, LLC:

- Dermik Laboratories: “A Pilot Multi-Center, Patient Preference Study Comparing Two XXX/XXX Gels for treatment of Acne.” (2005-2006)
- Graceway Pharmaceuticals “Open Label Safety and Pharmacokinetic Study of XXX for One, Two, or Three Treatment Cycles to Surface Areas Greater than 25 square centimeters with Actinic Keratosis. (2005-2007)
- Allergan “A Double Blind Dose Comparison of the Safety and Efficacy of XXX in the treatment of Female Subjects with Moderate or Severe Glabellar Rhytides. (2006)
- Galderma: “A Multi-center, Randomized, double blind, Parallel-group Study to demonstrate the Efficacy and Safety of XXX in Subjects with Acne Vulgaris”. (2006-Present)
- Peplin “A multi-center, randomized, double-blind, double dummy, vehicle –controlled sequential cohort study to determine the safety of XXX in patients with Actinic Keratoses”. (2006-2007)
- Allergan “Comparative Effectiveness and Safety of XXX vs. XXX in Lip Augmentation Pilot Study”. (2007)
- CollaGenex “A Multi-Center Randomized, Double-Blind, Active-Control Clinical Trial to Determine the Effects of XXX in Patients with Moderate to Severe Rosacea. (2007)
- Johnson & Johnson “The Pump Study” An Open Label, Community Based, Phase Four Study to assess Facial Acne Improvement with the use of XXXX. (2007)
- “A Multi-Center, Double-Masked, Parallel Study Assessing the Safety and Efficacy of Once-Daily Application of XXX Solution Compared to Vehicle in Increasing Overall Eyelash Prominence”. (2007)
- Allergan “A Multi-Center, Open Label Feasibility Study of the Safety and Effectiveness of XXX Injectable Gel in Subjects Who Desire Lip Enhancement”. (2007-2008)
- “A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of XXX 0.1% Compared With Vehicle Lotion in Subjects with Acne Vulgaris”. (2008-Present)
- Artes Medical “Protocol for the Post-Approval Study of XXX for Correction of Nasolabial Folds”. (2007-Present)
- MS-1000, “Study of Cryo-Remodeling for Facial Enhancement”. (2007-Present)
- XXX-PSOR-201 “A Phase II Study of the Dose-Effect of XXX Ointment in Patients with Plaque-Type Psoriasis”. (2008-Present)
- ARTES Medical “Protocol for the Post-approval Study of Artefill for Correction of Nasolabial Folds. (2008)
- Abbott Labs. Psoriasis – M06-890. April 2008

- Warner Chilcott “A Randomized Double Blind Study to Evaluate the Safety and Efficacy of three Doses of a New Oral Formulation of XXXX as Compared to Placebo in the Treatment of Moderate to Severe inflammatory Facial Acne Vulgaris. (2008)
- STIEFEL: A Phase III Multicenter Randomized Double Blind Active and Vehicle Controlled Study of the Safety and Efficacy of XXXX Gel Verses XXX Gel Verses XXXX Gel Verses Vehicle in Subjects with Acne Vulgaris. (2008)
- Actavis Mid-Atlantic LLC “A Multicenter Double Blind Randomized Parallel Group Vehicle Controlled Study to Determine the Clinical Equivalence of Generic XXXX and XXXX Cream in Subjects With Actinic Keratosis. (2008)
- Abbot “A Phase III Multicenter Randomized Double Blind Placebo controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens XXXX to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis. (2008)
- Galderma “Open Label Randomized Split Face Study to Evaluate the Efficacy Safety and Subject Satisfaction of pain Management During and After XXXX Dermal Filler Injections for the Correction of Nasolabial Folds. (2008)
- Taro, Inc. “A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two XXXX Topical Ointment Formulations in Patients with Moderate to Severe Atopic Dermatitis”. (2008-2010)
- Dow “A Phase 2B Multi-Center, Double-Blind, Randomized, Dose-Ranging Clinical Trial to Evaluate XXXX in the Treatment of Moderate to Severe Acne Vulgaris with Nodular Involvement”. (2008-2009)
- A Placebo-Controlled, Double-Blind, 2-Dose-Level (50mg and 200mg TID) Study of a 28-Day Treatment with XXXX Tablets in Adult Patients with Atopic Dermatitis. (2009-2010)
- Nycomed, Inc.: “A Multi-Center, Double Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing XXXX to XXXX and Both Active Treatments to a Vehicle Control in the Treatment of Atopic Dermatitis”. (2009-2010)
- Basilea “Efficacy and Safety of XXXX in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy.” (2008-2012)
- Serentis “A Phase II, Randomized, Double-Blind, Vehicle Controlled, Cross-Over Study to Determine the Anti-Pruritic Efficacy, Safety and Local Dermal Toleration of XXXX Cream in Subjects with Atopic Dermatitis”. (2009-2010)
- Galderma, “A Phase 4, Open-Label, Multi-Center, Community-based, 12-week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction with XXXX XXXX When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea. (2009-2010)
- Peplin, “A multi-center, Randomized, Parallel Group, Double-Blind, Vehicle-Controlled study to evaluate the Efficacy and safety of XXXX In Patients with Actinic Keratoses on the head, face or scalp. (Region-IIb) (2009-2010)
- Myoscience, “Study of Cryo-Remodeling for Facial Enhancement: A Prospective, Non-Randomized Study to Evaluate the Performance of the Myoscience Cryo-Remodeling Device for the Treatment of Glabellar Lines (Frown Lines), Lateral Orbital Lines (Crow’s Feet), Perioral Lines and Frontalis Lines (Horizontal Forehead Lines). (2008-2010)

- Pacific Biosciences Laboratories, Inc.: A One Day Research Study Designed to Evaluate the Immediate Effects of Your Fine Lines/Wrinkles Around Your Eyes When a Sonic Applicator is Used to Apply a Serum to the Crow's Feet and Under Eye Area. (2009-2010)
- ISOCT.08.01 A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of XXXX in Patients with Severe Recalcitrant Nodular Acne. (2010 - 2011) Protocol Number: RD.06.SPR.18161 A 4-Week, Randomized, Double-Blind, Parallel-Group, Vehicle- Controlled, Multicenter Study Investigating the Efficacy and Safety of XXXX Applied Topically Once Daily (QD), and XXXX Topically Once Daily(QD) or Twice Daily (BID), in Subjects with Moderate to Severe Facial Erythema Associated with Rosacea. (2010-2011)
- DPSI-IDP-108-P3-02 A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Safety and Efficacy of XXXX Topical Solution versus Vehicle in Subjects with Mild to Moderate Onychomycosis of the Toenails. (2010-2011)
- 191622-099 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy XXX Type A) Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow's Feet Lines and Glabellar Lines). (2011- 2012)
- A Multicenter Double Blind Randomized Vehicle Controlled Dose Range Study of XXXX and Vehicle Gel in the treatment of Rosacea. (2011-2012)
- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of XXXX Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area. (2011-Present)
- A Multicenter Double Blind Randomized Vehicle Controlled Dose Range Study of Encapsulated XXXX and Vehicle Gel in the Treatment of Rosacea. (2011-2012)
- Phase 3 Randomized Study of the Use of XXXX for Moderate to Severe Atrophic Facial Scar Correction. (2012-2013)
- A Phase 3b, Randomized, Double-blind, Active-Controlled, Multicenter Study to Evaluate a "Subject-Tailored" Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis. (2012-Present)
- A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly XXXX with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly XXXX in Diabetes - 8). (2012-2013)
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with XXXX in Subjects with Type2 Diabetes Mellitus. (2012-Present)
- A 64-week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous XXXX, Followed by an Optional Long Term Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis. (2012-2013)
- A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel-Group Clinical Trial to Assess the Safety and Efficacy of XXXX Topically Applied Twice Daily for 12 Weeks in Patients with Papulopustular Rosacea. (2012-2013)



- Randomized Double-Blind Double-Dummy Placebo Controlled Study of the Safety and Efficacy of XXXX and Immediate Release XXXX in the Treatment of Symptoms of Acute Upper Respiratory Tract Infections for Seven Days. (2011-2012)
- A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of XXXX Compared with Placebo and XXXX in Subjects with Moderate to Severe Plaque Psoriasis. (2011-2015)
- Janssen (Johnson & Johnson). Psoriasis Study – CNT01275-PSO-3009. May 2012
- Amgen Inc. Psoriasis – 20120104. November 2012
- LEO 80185-G23 XX plus XXX XXX Topical Suspension Compared to XXX XXX in the Topical Suspension Vehicle, XXX in the Topical Suspension Vehicle and the Topical Suspension Vehicle Alone in Psoriasis Vulgaris. (2012-2013)
- A Multicenter Randomized Placebo-Controlled Double-Blind Parallel Study to Evaluate the Efficacy and Safety of XXXX in Adult Subjects with Atopic Dermatitis. (2012-Present)
- A Sequential Treatment Regimen of Cryotherapy and XXXX Field Therapy Compared to Cryotherapy Alone for the Treatment of Actinic Keratosis. (2012-2013)
- A Safety and Efficacy Study to compare Dapsone Dermal Gel with Vehicle Control in Patient with Acne Vulgaris. (2013-2014)
- Content Validity of Patient-Reported Outcome Items to Assess Aesthetic Improvement Associated with Cellulite Treatment in a Patient Population with Cellulite. (2013-2014)
- A 48 Week Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-Ranging, Active-Comparator-Controlled (Ustekinumab), Double-Blind within Dose Groups of BI 655066. (2013-Present)
- A Randomized, Double-Blind, Vehicle Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% vs Dipropolene (Augmented Betamethasone Dipropionate) Lotion 0.05% and the Efficacy of Betamethasone Dipropionate Spray 0.05% vs Vehicle Spray in the Treatment of Moderate Plaque Psoriasis. (2013-2014)
- A Multicenter Double Blind Randomized Vehicle Controlled Dose Range Study of Encapsulated Benzoyl Peroxide Gel 1% and 5% and Vehicle Gel in the Treatment of Rosacea. (2013-2014)
- Phase 3 Randomized Study of the Use of Artefill for Moderate to Severe Atrophic Facial Scar Correction Evidera Cellulite Questionnaire Study. (2013-2014)
- A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene foam 0.005%, Versus Vehicle Foam in Pediatric Subjects (ages 2 to 11 Years) with Plaque Psoriasis. (2013-2014)
- A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis. (2013-Present)

- A Study Evaluating the Effect of Poly laser Dry Mask in Combination with the Polyhydrate Mask as an Adjunctive Agent in Ablative or Fractional Ablative Laser Resurfacing. (2013-Present)
- A Study Evaluating the Effect of Polyhydrate Mask as an Adjunctive Agent in Cosmetic Facial Procedures. (2013-Present)
- A Study Evaluating the Effect of Polyhydrate Lip and Crows Feet Masks as Adjunctive Agents in Cosmetic Facial Procedures. (2013)
- A Study Evaluating the Effect of a Polyhydrate Mask as an Adjunctive Agent in Microdermabrasion Treatment. (2013)
- A Multicenter, Open-Label Study of the Long-Term Safety of AN2728 Topical Ointment, 2% in the Treatment of Children and Adolescents (Ages 2-17 Years) With Atopic Dermatitis. (2014-Present)
- A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared with Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis. (2012-Present)
- Merck. Psoriasis Study – Merck 10 PSO-MK 3222-010-00. January 2013
- Lilly. Psoriasis Study – 1F-MC-RHBA(b). September 2013
- A Phase 2 Randomized Double Blind Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy. (2014)
- A Phase 2 Randomized Double Blind Vehicle Controlled Dose Ranging Study of the Effect of Drm04B in Subjects with Axillary Hyperhidrosis. (2013-2014)
- Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm on the Chest in Subjects with Actinic Keratosis. (2013-2014)
- A Phase 3 Trial Comparing Once Daily Treatment with LEO 90100 Calcipotriol 50mcg/g plus Betamethasone 0.5mg/g with Vehicle in Subjects with Psoriasis Vulgaris. (2013-Present)
- A Follow-up Evaluation of Study Subjects treated in Protocol ISOCT.08.01 - the Phase 3 Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy and Safety of Cipisotretinoin in Patients with Severe Recalcitrant Nodular Acne. (2013-2014)
- Evaluation of the Ulthera® System for Lifting and Tightening of Facial and Neck Skin Laxity Using a Customized, High-Density and Vectoring Treatment Approach. (2013-2014)
- BLI1100-202 A randomized, controlled evaluation of the safety and efficacy of topical treatments for moderate-severe facial acne vulgaris. (2014)
- A Multi-Center Randomized, Double Blind parallel-Group Vehicle and Active Controlled Study to Compare the Efficacy and Safety of XXXX Topical Gel Versus Topical Gel Vehicle in Subjects with Acne Vulgaris. (2014)
- Efficacy and Safety of Oxymetazoline HCl 1.0% for the Treatment of Persistent Erythema Associated with Rosacea. (2014)

- Content Validity of Patient-Reported Outcome Items to Assess Aesthetic Improvement Associated with Cellulite Treatment in a Patient Population with Cellulite. (2014)
- A Double-Blind, Randomized, Parallel-group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 DP Versus Enbrel in Subjects with Chronic Plaque Psoriasis (CHS-0214-04). (2014)
- A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Four-Arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects with Mild/Moderate Atopic Dermatitis. (2014)
- A Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Phase II Dose-Ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients with Actinic Keratoses (AK). (2014)
- Study drug AGN-225678 entitled 225678-006. This is a safety and efficacy study to compare Dapsone Dermal gel with vehicle control in patients with Acne Vulgaris.
- Efficacy and safety of Oxymetazoline HCl Cream 1.0% for the treatment of persistent erythema associated with rosacea.
- A 48-week study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomized, dose-ranging, active-comparator-controlled (ustekinumab), double-blind within dose groups of BI 655066)
- A multi-center open label evaluation of the safety of Sarecycline Tablets in the treatment of Acne Vulgaris.
- A phase 2, randomized, double-blind, vehicle-controlled, dose-ranging study of DRM01B Topical Gel in subjects with Acne Vulgaris.
- A randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of 1.5 mg/kg per day of Sarecycline compared to placebo in the treatment of Acne Vulgaris.
- A phase 2B double-blind, randomized, placebo-controlled, parallel group, dose-ranging study to assess the efficacy, safety and tolerability of PF-04950615 following monthly and twice monthly subcutaneous dosing for six months in hypercholesterolemic subjects on a statin.
- A phase 2 multicenter, randomized, double-blind, placebo-controlled trial to evaluate Toreforant (JNJ-38518168) for the treatment of subject with moderate to severe plaque-type psoriasis.
- A phase 3b, randomized, double-blind, active-controlled, multicenter study to evaluate a 'subject-tailored' maintenance dosing approach in subjects with moderate to severe plaque psoriasis.
- Efficacy and safety of Ingenol Mebutate Gel in field treatment of Actinic Keratosis on full face, balding scalp, or approximately 250 cm<sup>2</sup> on the chest.

- A double-blind, randomized, parallel-group, active-control study to compare the efficacy and safety of CHS-0214 DP versus Enbrel in subjects with chronic plaque psoriasis (CHS-0214-04)
- IND 101,389: A 64-week, Phase 3, randomized, placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous SCH 900222/MK-3222, followed by an optional long-term safety extension study, in subjects with moderate to severe chronic plaque psoriasis (protocol No. MK-3222-010)
- Medivector. Influenza – T705a US317. January 2014
- A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira in patients with moderate to severe chronic plaque-type psoriasis.
- A multi-center, double blind, randomized, vehicle controlled, parallel-group study to compare Perrigo UK FINCO's Brimonidine topical gel 0.33% to Mirvaso (Brimonidine) topical gel 0.33% and both active treatments to a vehicle control in the treatment of persistent (nontransient) facial erythema of rosacea.
- Safety and Efficacy of escalating doses of Ingenol Mebutate once daily for two or three consecutive days when used on full face full balding scalp or approximately 250 cm<sup>2</sup> on the chest in subjects with actinic keratosis.
- Boehringer Ingelheim Pharma. Psoriasis – BI PSO 1311.2. March 2014
- BLI1100-202 A randomized, controlled evaluation of the safety and efficacy of topical treatments for moderate-severe facial acne vulgaris.
- A phase 2 study comparing treatment with LEO 90100 with calcipotriol and beta-methasone ointment, LEO 90100 vehicle and ointment vehicle in subjects with psoriasis vulgaris.
- Anacor Pharma. Atopic Dermatitis – AN2728-AD-302. April 2014
- A double blind prospective, randomized, vehicle-controlled, multi-center study of photodynamic therapy with Visonac Cream in patients with acne vulgaris.
- A multi-center, double blind, randomized, vehicle-controlled dose range study of encapsulated Benzoyl-Peroxide Gel 1% and 5% and vehicle gel in the treatment of rosacea.
- A randomized, double-blind, vehicle-controlled, multi-center, parallel-group clinical trial to assess the safety and efficacy of Azelaic Acid Foam 15%, applied topically twice daily for 12 weeks in patients with papulopustular rosacea.
- Anacor Pharma. Atopic Dermatitis. AN2728-AD-303. June 2014
- A multi-center, randomized, double-blind, parallel-group vehicle and active-controlled study to compare the efficacy and safety of CD0271 0.3%/CD1579 2.5% topical gel versus topical gel vehicle in subjects with acne vulgaris.
- A phase 3 trial comparing once daily treatment with LEO 90100 Calcipotriol 50mcg/g plus Bethamethasone 0.5mg/g with vehicle in subjects with psoriasis vulgaris.
- Boehringer Ingelheim Pharma Inc. Psoriasis Study – BI PSO EXT 1311.13. Year: 2014
- Coherus. Psoriasis Study – CHS-0214-04. September 2014

- Leo Pharma. Psoriasis Study – Leo LP0053-1003. September 2014
- Sebacia Inc. Acne Study – SEB-0121. September 2014
- G&E Herbal Biotechnology Co. Ltd. Actinic Keratosis Study – G&ESR-T100AK. Year: 2014
- Otsuka Pharma. Atopic Dermatitis – OPA-15406. November 2014
- Janssen (Johnson & Johnson). Psoriasis Study – CNT01959PSO3003. December 2014
- Stiefel Laboratoris Inc. Psoriasis Study – STF115469. Year: 2014
- Polyremedy. Acne – PRO 2014-02. December 2014
- DermaVance. Nasolabial Folds Study – DA-13-007. December 2014
- Janssen (Johnson & Johnson). Psoriasis Study – 38518168PSO2001. January 2015
- Sandoz. Psoriasis Study – PSO GP17-301. January 2015
- Activas Mid-Atlantic LLC. Acne – SC1401. February 2015
- Janssen (Johnson & Johnson). Psoriasis – CNT01959PSO3002. February 2015
- Regeneron Pharma. Atopic Derm – R668-AD-1224. February 2015
- Evidera. Genital Psoriasis – EVA-16679-00. March 2015
- Mimetica Pty Ltd. Acne – MCL15001. March 2015
- Dermira. Acne – DRM01B-ACN02. April 2015
- Neothetics. Subcutaneous Fat – CL-19. April 2015
- Leo Pharma. Actinic Keratosis – LP0105-1032. April 2015
- Perrigo New York Inc. Actinic Keratosis – AK PRG-NY-15-002. June 2015
- Novartis. Psoriatic Arthritis – CAIN457FUS01. June 2015
- Actavis Mid-Atlantic LLC. Atopic Derm – SC1403. June 2015
- Allergan. Wrinkles – Impressions 191622-143. June 2015
- Perrigo UK Finco Ltd. Partnership. Rosacea – PRG-NY-14-022. June 2015
- Neothetics. Subcutaneous Fat – CL-23. July 2015
- Valeant. Psoriasis – PSO V01-118A-303. August 2015
- Dermira. Hyperhidrosis – DRM04-HH05. September 2015
- Revance. Hyperhidrosis – RT001-CL045. September 2015
- Galderma. Nasolabial Folds – Sculptra GLL04.SPR.US10321. October 2015
- Cutanea. Acne – CLS001-CO-PR-009. October 2015
- Braintree Labs. Acne Vulgaris – BLI1100-203. October 2015
- Teva. Actinic Keratosis – SYM 2015-01. November 2015

- Promius. Psoriasis – PSO DFD-060CD-005. November 2015
- Dermira. Hyperhidrosis – DRM04-HH06. November 2015
- Leo Pharma. Actinic Keratosis – AK LP0084-1194. November 2015
- Cassiopea. Acne Vulgaris – CB-03-01/25 & 27. December 2015
- Revance. Wrinkles – 1620302. January 2016
- Valeant. Acne Vulgaris – AV V01-120A-201. January 2016
- Suneva Medical. Acne Scarring – SUN-15-04. January 2016
- Vanda. Pruritis – VP-VLY-686-2102. February 2016
- Aclaris. Seborrhic Keratosis – A-101-SEBK-303. February 2016
- Ralexar Therapeutics, Inc. Atopic Dermatitis – ALX-101. March 2016
- Endo Pharma. Cellulite – EN-3835-201. March 2016
- Evidera. Psoriasis – EVA-18225-000. March 2016
- Perrigo UK Finco Ltd Partnership. Rosacea – PRG-NY-15-013. March 2016
- Boehringer Ingelheim Pharma. Psoriasis – BI Psoriasis 1311.4. April 2016
- Dermira. Acne Vulgaris – DRM01B-ACN04. April 2016
- Therapeutic, Inc. Psoriasis – TI SOP 305-A. May 2016
- Novartis. Axial Spondyloarthritis – CAIN457H2315. May 2016
- Merz. Wrinkles – P151009. June 2016
- Ulthera. Facial Laxity – ULT-146. July 2016
- Actavis Mid-Atlantic LLC. Rosacea – ACTA/AZEL/2015. July 2016
- Allergan. Weak Chin – VOLUMA-006. August 2016
- BioPharmX. Acne Vulgaris – BPX-01-C03. August 2016
- Evidera. Psoriasis – A18225-01. September 2016
- Medimetriks Pharma. Atopic Dermatitis – MEDI-MM36-206. September 2016
- Therapeutics, Inc. Psoriasis – 122-0551-310. September 2016
- Valeant. Psoriasis – PSO V01-118A-301. September 2016
- Channel. Clarity CIP 0101. September 2016
- Novartis. Psoriasis – CAIN457A2326. October 2016
- Valeant. Psoriasis – PSO V01-122A-301. October 2016
- Sienna Labs. Acne – 1064-1100-fa. October 2016
- Dermavant. Atopic Dermatitis – RVT-501-1001. October 2016

- Galderma. Acne – GLL04.SPR.US10355. October 2016
- Allergan. Acne – 1679-401-006. January 2017
- DPT Labs. Atopic Dermatitis – CD-14-875. February 2017
- Gage Development Co. Actinic Keratosis – GDC-695-001. February 2017
- Dermira. Acne Vulgaris – DRM01B-ACN05. March 2017
- Sienna Labs. Acne Vulgaris – SL\_2016\_01\_FA. March 2017
- Pfizer. Psoriasis – B7931004. May 2017
- Dermira. Hyperhidrosis – DRM04-HH07. June 2017
- Leo Pharma. Psoriasis – LP0053-1004. June 2017
- Leo Pharma. Skin Cancer – LP0084-1369. June 2017
- Sienna Labs. Cosmetic – Sienna 755.1000. August 2017
- Valeant. Acne Vulgaris – V01-123A-301. August 2017
- Sebacia Inc. Acne Vulgaris – SEB-0493. November 2017
- AbbVie. Psoriasis – M15-997. February 2018
- Dermira. Moderate-to-severe Atopic Dermatitis – DRM06-AD01. April 2018
- Vanda. Treatment-Resistant Pruritus Associated w/Atopic Dermatitis – VLY-686-3101. July 2018
- Symbio. Topical Cream in the Treatment of Papulopustular Rosacea – SGT-54-02. August 2018
- Aclaris. Topical Solution for Common Warts – A-101-Wart-301. October 2018
- Syntrix. AMT-PSO-201. October 2018
- Syntrix. Efficacy and Safety of Oral Aminopterin for the Treatment of Moderate-to-Severe Psoriasis. AMT-PSO-201. October 2018
- Glenmark. Moderate-to-Severe Atopic Dermatitis. GBR-830-204. November 2018
- Valeant. Safety & Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the treatment of Acne Vulgaris. January 2019
- Kadmon. A Phase 2, Randomized, Placebo-controlled, Double-Blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis. KD-25-209. February 2019
- Therapeutics. A Multicenter, Randomized, Double-Blind, Vehicle controlled, proof of concept Comparison Study of the Safety and Efficacy of DUR-928 Topical Solution with occlusion in subjects with mild to moderate Plaque Psoriasis. C928-015. February 2019
- Valeant. A Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in Pediatric Subjects with Moderate to Severe Plaque Psoriasis. V01-122A-401. April 2019

- Menlo. A Randomized, Double-Blind, Placebo controlled study of the efficacy, safety and tolerability of Serlopitant for the treatment of Pruritus in adults with Prurigo Nodularis. MTI-105. May 2019
- AbbVie. A phase 3B Multicenter, Randomized, Double-blind, Double-Dummy, Active Controlled Study comparing the safety and efficacy of Upadacitinib to Dupilumab in adult subjects with moderate to severe Atopic Dermatitis. M16-046. May 2019
- Dermavant. Open-label maximal use study to evaluate the safety, tolerability and pharmacokinetics of Tapinarof Cream 1% in adults with extensive plaque psoriasis. DMVT-505-2002. July 2019
- Kiniksa. A phase 2 randomized, double-blind, placebo-controlled pilot study to investigate the efficacy, safety and tolerability of KPL-716 in reducing Pruritus in diseases characterized by chronic pruritus. KPL-716-C2020. August 2019
- Qurient. A multicenter, randomized, phase 2, double-blind, vehicle-controlled, parallel group comparison study to evaluate the safety and efficacy of Q301 cream in adolescents and adults with mild to moderate atopic dermatitis. Q301-AD-P-US002. August 2019
- Eli Lilly. Phase 1, multicenter, randomized, placebo-controlled, triple-blind, single-ascending dose and repeat dose trial in healthy participants and participants with atopic dermatitis. J1B-MC-FRCC. September 2019
- Foamix. A prospective, multicenter, randomized, double-blind, vehicle-controlled phase 2 study to evaluate the safety and efficacy of a combination of 3% Minocycline and 0.3% Adapalene Topical Foam formulation for the treatment of moderate-to-severe Acne. FX2016-40. September 2019
- Menlo. An open-label long-term safety study of Serlopitant for the treatment of Pruritus. MTI-107. September 2019
- Arena. A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (with a 52-week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects with Moderate to Severe Atopic Dermatitis. November 2019
- Dermira. A Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the efficacy and safety of Lebrikizumab in patients with moderate to severe atopic dermatitis. December 2019
- AbbVie. A phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of Risankizumab in adult subjects with moderate to severe Hidradenitis Suppurativa. January 2020
- Galderma. A randomized, double-blind, vehicle-controlled, multicenter study to assess the efficacy and safety of Methyl Aminolevulinic Acid Hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT). January 2020
- Recros Medica. The INFORM Study: A multi-center study to evaluate the safety and efficacy of Rotational Fractional Resection on Submental Contouring with an optimized post-procedure treatment plan. February 2020



- Valeant. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group, clinical study comparing the efficacy and safety of IDP-126 Gel in the treatment of Acne Vulgaris. February 2020
- Trevi. A phase 2b/3, randomized, double-blind, placebo-controlled, 2-arm, efficacy and safety study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus relief through itch scratch modulation (PRISM Study). May 2020
- AbbVie. A phase 3b, open-label treatment extension study of Upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in study M16-046. June 2020
- Galderma. A double-blind, multicenter, long-term follow-up study to assess recurrence of Actinic Keratosis in subjects treated with Methyl Aminolevulinic Acid Hydrochloride (MAL) 16.8% cream (CD06809-41) or vehicle cream in the treatment of thin and moderately thick, nonhyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT), for subjects achieving complete response of treated lesions at final visit in study RD.06.SPR.112199. July 2020
- Novan. A phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study comparing the efficacy and safety of SB206 and vehicle gel once daily in the treatment of Molluscum Contagiosum. September 2020
- Dermira. A long-term study to assess the safety and efficacy of Lebrikizumab in patients with moderate to severe atopic dermatitis. February 2021
- Eli Lilly. A phase 3, 16-week, randomized, double-blind, placebo-controlled, parallel-group study to assess the impact of Lebrikizumab on vaccine responses in adult patients with moderate to severe Atopic Dermatitis. March 2021
- Valeant. Acne Vulgaris. V01-126A-202. April 2021
- AbbVie. Platysma Prominence. M21-326. August 2021
- AbbVie. Moderate Plaque Psoriasis. M20-326. August 2021
- DermTech. Biomarkers in Atopic Dermatitis. 20-03. October 2021
- AbbVie. Glabellar Lines. 2042-201-008. October 2021
- AbbVie. Glabellar Lines. M21-509. March 2022
- Meiji Seika. Moderate-to-Severe Psoriasis. ME318-3. April 2022
- Janssen (Johnson & Johnson). Moderate-to-Severe Plaque Psoriasis. 7724213PSO2001. April 2022
- RAPT Therapeutics. Moderate-to-Severe Atopic Dermatitis. RAPT RPT193-02RZA15406. May 2022
- Incyte. A Phase 2b/3 Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participatns with Prurigo Nodularis. INCB18424-319. 2022
- DermBiont. An Observer-Blinded, Randomized, Aqueous Gel Controlled Trial of the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects with Interdigital Tinea Pedis. June 2022

- RAPT Therapeutics. A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis. RPT193-02 RZA15406. July 2022
- Merck. A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-6194 in Participants with Moderate-to-Severe Atopic Dermatitis. MK6194-008. August 2022
- AbbVie. M23-365. August 2022
- AbbVie. Platysma Prominence: Open-Label Extension Study of BOTOX Treatment for Platysma Prominence. M21-323. September 2022
- Cara Therapeutics. A Two-Part, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects with Atopic Dermatitis. CR845-310501. October 2022

### **Editorial Boards**

2008 – Present	<b><i>SKINmed Journal: Dermatology for the Clinician</i></b> , Editorial Board
2007 – Present	<b><i>Journal of Clinical and Aesthetic Dermatology</i></b> , Aesthetic Editor-in-Chief, Matrix Medical Communications
2006 – Present	<b><i>Cosmetic Dermatology</i></b> , Editor-in-Chief, Quadrant Healthcom, Inc.
2006 – Present	<b><i>Aesthetic Buyers Guide</i></b> , Editorial Advisory Board, Medical Insight, Inc.
2006 – Present	<b><i>Dermatology Times</i></b> , Editorial Council, Advanstar Communications
2006 – Present	<b><i>Medesthetics: Business Education for Medical Practitioners</i></b> , Advisory Board, Creative Age Publications.
2003 – Present	<b><i>Journal of Drugs in Dermatology</i></b> , International Editorial Board, Strategic Communication in Dermatology, Inc.
2001 – Present	<b><i>Cutis</i></b> , Editorial Advisory Board, Quadrant Healthcom, Inc.
2001 – 2006	<b><i>Cosmetic Dermatology</i></b> , Senior Editor, Quadrant Healthcom, Inc.
2001 – 2004	<b><i>Triple I Podiatry Prescribing Guide</i></b> , Editorial Advisory Board, MediMedia USA, Inc.
2001 – 2004	<b><i>Pathways to Clinical Practice</i></b> , Editor, Quarterly Newsletter, HMP Publications, Inc.
1999 – 2012	<b><i>Skin &amp; Aging</i></b> , Editorial Advisory Board, Contributing Editor,

1997 – 1999

***Progressive Clinical Insights***, Editorial Board, Contributing Editor,  
Paramedical Consultants, Inc.

**Publications**

- Werschler, WP, Elgart, ML, Williams, CM. Progressive asymptomatic annular facial skin lesions. Cutaneous tuberculosis. Archives of Dermatology. September 1990. Vol 126 (9): 1227, 1229-1230.
- Werschler, WP. Total Intravenous Anesthesia for Office-Based Laser Facial Resurfacing. Lasers in Surgery and Medicine; Supplemental 9, 1997:34.
- Werschler, WP, et al. Cosmetic Office Practice – A Novel Perspective. Progressive Clinical Insights, January/February 1998; Vol. 6(1): 24-25.
- Werschler, WP. Why the Time is Now to Promote Cosmetic Procedures. Skin & Aging, April 1998; Vol. 6(4): 32-33.
- Werschler, WP. How You Can Integrate Cosmetic Procedures Into Your Practice. Skin & Aging, May 1998; Vol. 6(5): 41-43.
- Werschler, WP. Overcome the Challenges of Adding Laser Procedures to Your Practice. Skin & Aging, July 1998; Vol. 6(7): 59-62.
- Trytko R, Werschler, WP. Total Intravenous Anesthesia for Office-Based Laser Facial Resurfacing. Lasers in Surgery and Medicine; Supplemental Vol 25(2), 126-130, 1999.
- Werschler, WP. Making Mid-level Providers Work for You. Skin & Aging, February 1999; Vol. 7(2): 53-57.
- Werschler, WP., et al. Emollients: Current Uses and Future Trends. Skin & Aging, June 1999 Supp.; Vol. 7(6).
- Werschler, WP. What to Do When the HMO Says “No!” Skin & Aging, August 1999; Vol. 7(8): 46-49.
- Werschler, WP. The Promise and Pitfalls of Private Practice. Skin & Aging, January 2000 Supp.; Vol. 8(1): 4-7.
- Werschler, WP. Wake Up Your Practice with These 13 Tips. Skin & Aging, February 2000; Vol. 8(2): 58-62.
- Werschler, WP. How to Introduce Liposuction into Your Practice. Skin & Aging, April 2000; Vol. 8(4): 39-45.
- Werschler, WP., et al. Rethinking Onychomycosis. Skin & Aging, July 2000 Supp.; Vol. 8(7).

- Werschler, WP. Botox: Inject New Life Into Your Practice. *Skin & Aging*, August 2000 Supp.; Vol 8(8)
- Parish, LC, Routh, HB, Miskin, B, Fidelholz, J, Werschler, P, Heyd, A, Haverstock, D, Church, D., Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. *International Journal of Clinical Practice*. October 2000; Vol 54(8):497-503.
- Werschler, WP. Eczema and Contact Dermatitis. *American Journal of Medicine and Sports*, 2000; Vol. 2(3): 178-181, 202.
- Werschler, WP with Craze, MG. *How to Develop, Manage & Market a Cosmetic Practice*, Text Book. PPMS, Spokane, WA.
- Werschler, WP, Bondar, GL, Smith, SS. Occupational Risks of Malignant Melanoma. *Clinics in Occupational and Environmental Medicine*, February 2001: 75-84.
- Werschler, WP. What You Need to Know About the Fickleness of Cash Flow. *Skin & Aging*, April 2001; Vol. 9(4): 27-28.
- Werschler, WP. Economic Forecasting For Practice Development. *Skin & Aging*, May 2001; Vol. 9(5): 21-22.
- Werschler, WP. Advice for Dispensing Prescription Pharmaceuticals. *Skin & Aging*, June 2001; Vol. 9(6): 22-24.
- Werschler, WP. How to Identify Problems with Your Practice. *Skin & Aging*, September 2001; Vol. 9(9): 91-93.
- Werschler, WP., Baumann, Leslie. Everything You Need To Know About Botox Injection. *Skin & Aging*, October 2001; Vol 9(10): 36-42.
- Werschler, WP. Mechanism of Drug Action Important to Consider. *Dermatology Times*, November 2001; Vol. 22 Supp. 5: S8-S9.
- Werschler, WP., et. al. (BOTOX Glabellar Lines I Study Group). "A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines" *Journal of American Academy of Dermatology*, 2002; 46:840-9.
- Werschler, WP., et al. Introducing a New Service in the Dermatology Practice. *Skin & Aging*, January 2002; Vol. 10(1): 43-47.
- Werschler, WP., et al. Treatment of Onychomycosis in the Elderly. *Clinical Geriatrics*, April 2002; Vol 10(4): 19-29.
- Werschler, WP. Mixed Infection and Urticarial Drug Reaction Following CO2 Laser/TCA Peel. *Cosmetic Dermatology*, August 2002; Vol. 15(8): 21-22.
- Werschler, WP. 10 Questions to Ask if You are Thinking About Receiving Botox Cosmetic Therapy. *Healthy Skin & Hair Summer*, 2002:7.
- Werschler, WP. A New Era of Actinic Keratosis Treatment. *Skin & Aging*, September 2002; Vol 10 Supplement 9: 1-15.
- Werschler, WP., et. al (Roundtable Participants). *Clinical Dialogues: Actinic Keratosis and Other Nonmelanoma Skin Cancers*. A Supplement to *Skin & Allergy News*, 2004.

- Werschler, WP., et. al. Assessing Treatment Outcomes in Toenail Onychomycosis Clinical Trials. *American Journal of Clinical Dermatology*, 2004; 5 (3): 145-152.
- Gupta, AK, Carney, PS, Jegasothy, SM, Turner, JE, and Werschler, WP, Onychomycosis: Management and Treatment. July 2004; Vol 74 (1S) 16-24.
- Werschler, WP, Hanke, W, and Weinkle, S, The Aging Face: More Than Skin Deep, July 2004.
- Carruthers, Jean, M.D., Fagien, Steven, M.D., Matarasso, Seth L., M.D., Werschler, WP., et. al. (the Botox Consensus Group). Introduction to the Consensus Recommendations. Supplement to *Plastic and Reconstructive Surgery*, November 2004; Vol 114(6): i-22S.
- Jorizzo, JL, Carney, PS, Ko, WT, Robins, P, Weinkle, SH, Werschler, WP. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule. *Cutis*, December, 2004; Vol 74 (6 Suppl): 18-23.
- Jorizzo, Joseph L., M.D., Carney, Patrick S., M.D., Ko, William T., M.D., Robins, Perry, M.D., Weinkle, Susan H., M.D., and Werschler, WP (Roundtable Participants). Which options when: How to Maximize the Treatment Outcomes for Actinic Keratosis. Supplement to *Cutis*, December 2004; Vol 74(6S): 4-25.Review.
- Jorizzo, JL, Carney, PS, Ko, WT, Robins, P, Weinkle, SH, Werschler, WP. Treatment Options in the management of actinic keratosis. *Cutis*. December 2004. Vol 74(6 Suppl):9-17. Review.
- Jorizzo, JL, Carney, PS, Ko, WT, Robins, P, Weinkle, SH, Werschler, WP. Matching patients with therapy. *Cutis*. December 2004. Vol 74 (6 Suppl): 5-8. Review.
- Werschler, WP, Bondar, GL, and Esch, PJ, 6 Simple Steps to Sculptra Success. *Skin & Aging*, January 2005; Vol 13(1): 56-59.
- Werschler, WP, and Weinkle, Susan, M.D.. Longevity of Effects of Injectable Products for Soft Tissue Augmentation. *Drugs in Dermatology*, January 2005: New Methods and Techniques; Vol 4(1): 20-27.
- Werschler, WP. Advances in Recognizing and Treating Facial Lipatrophy. A Supplement to *Cosmetic Dermatology*, February 2005; Vol 18(2 S2): 1-4.
- Werschler, WP and Harland, Brad, C.P.A. Practice Pearls: Monitoring the Financial Health of Your Practice. *Skin & Aging*, February 2005; Vol 13(2):18-19.
- Werschler, WP and Harland, Brad, C.P.A. Practice Pearls: Should You Use a Cost-Sharing Agreement? *Skin & Aging*, March 2005; Vol 13(3): 31-32.
- Werschler, WP and Mest, Douglas R., MD. Questions and Answers: ASCDAS 3rd Annual Meeting – New Options in the Recognition and Treatment of Lipoatrophy with Volume Restoration. *Cosmetic Dermatology*, March 2005; Vol 18(3): 235-239.
- Werschler, WP (Moderator), Berson, Diane S., MD, Weinkle, Susan H., MD, Weiss, Jonathan S., and Woodson, Johnnie M., MD. The Expanding Role of 5-FU in Dermatology. Supplement to *Dermatology Times*, April 2005.
- Werschler, WP and Harland, Brad, C.P.A. Practice Pearls: Avoid Employee Theft: Implement Internal Controls. *Skin & Aging*, May 2005; Vol 13(5): 33-34.
- Werschler, WP and Vleggaar, Danny, MD. Fillers to Sculptors: Addressing Volumetric

Restoration / New Treatment Options in Lipoatrophy. Supplement to Dermatology Times, August 2005.

- Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. Practice Pearls: Choosing the Right Paid-Leave Policy. *Skin & Aging*, September 2005; Vol 13(9); 37-40.
- Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. Establishing and Evaluating Patient Satisfaction with your Practice. *Cosmetic Dermatology*, October 2005; Vol 18 (10); 699-701.
- Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. Practice Pearls: Should you Start your own Practice or Join an Existing One? *Skin & Aging*, October 2005; Vol 13 (10); 33-36.
- Werschler, WP. Achievements in Cosmetic Dermatology Recognized at ASCDAS Meeting, Guest Editorial. *Cosmetic Dermatology*, January 2006; Vol 19 (1); 21.
- Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. Promoting the Growth of Your Cosmetic Practice. *Cosmetic Dermatology*, January 2006; Vol 19 (1); 31-34.
- Werschler, WP, Rendon, Marta, MD, and Ditre, Cherie, MD. Facial Volume Restoration: Selecting and Applying Appropriate Treatments. *Cosmetic Dermatology Supplement*, February 2006; Vol 19 (2 S1); 1-12.
- Werschler, WP, et.al. Atopic Dermatitis: Emerging Therapies. Supplement to *Skin & Aging*, February, 2006.
- Werschler, WP, Eichenfield, LF, Chamlin, SL, Friedlander, SF. Recent Advances in the Management of Atopic Dermatitis. Supplement based on a faculty clinical roundtable discussion, affiliation with Skin Disease Education Foundation's 30th annual Hawaii Dermatology Seminar, February 2006.
- Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. The Growing Role of Physician Extenders, Part 1. *Skin & Aging*, March 2006; Vol 14 (3); 29-31.
- Werschler, WP, et. al. Don't Leave the Wrong Impression on Your Cosmetic Patient. *Cosmetic Dermatology*, April 2006; Vol 19 (4); 275-276.
- Werschler, Larson, Kari, BBA, and Harland, Brad, CPA. Using Physician Extenders, Part 2. *Skin & Aging*, May 2006; Vol 14 (5); 30-32.
- Werschler, WP, Cohen, JL, and Hirsch, RJ. ASCDAS 4th Annual Meeting Q&A's, *Cosmetic Dermatology* May 2006 Vol 19 (5); 337-338.
- Maley, Catherine, MBA, Werschler, WP, and Larson, Kari, MBA. Thinking About Adding a Laser to Your Practice? Renting Versus Owning. *Cosmetic Dermatology*, June 2006; Vol 19 (6); 400-402.
- Werschler, WP, Radiesse and Other Soft Tissue Fillers. *Aesthetic Trends & Technologies*, Summer 2006; Vol 5 (4)
- Werschler, WP, Berg, Roy, Larson, Kari. "Medical Equipment: Buy or Lease?" *Skin & Aging*, July 2006; 38-40.
- Werschler, WP, Larson, Kari, Harland, Brad. "Promoting the Growth of Your Cosmetic Practice". Volume 14 (3); 6.

- Werschler, WP. "Vivelif Offers New Technology for Wrinkles". Aesthetic Buyers Guide, September/October 2006; 3.
- Werschler, WP. "U.S. Fillers Market Set to Boom" Cosmetic Surgery Time, October 2006. Vol.9 (9); 12-14.
- Werschler, WP, Fried, R. Cover Article "The Key to Mastering Cosmetic Dermatology Patient Selection". Skin & Aging, October, 2006; Vol 14(10): 42-50.
- Werschler, WP. "Fillers, Toxins, Lasers, and More at the Annual ASCDAS Meeting". Cosmetic Dermatology, November 2006; Vol 19(11): 668
- Werschler, WP; Smith, Scott, DO. "Mechanism of Action of Poly-L-Lactic Acid: A Stimulatory Dermal Filler". Supplement to Journal of Drugs in Dermatology, January 2007: Vol 6(1):18-20
- Werschler, WP. "Hitting the Cosmetic Dermatology Jackpot". Cosmetic Dermatology. January 2007; Vol 20(1) Editorial 14
- Fagien, Steven, MD, FACS; Cox, Sue Ellen, MD; Finn, Charles, MD; Werschler, WP, Kowalski, Jonathan, PharmD, MS. "Patient-Reported Outcomes with Botulinum Toxin Type A Treatment of Glabellar Rhytids: A Double-Blind, Randomized, Placebo-Controlled Study". Dermatologic Surgery, January 2007; Vol 33(1): S2-S9 ISSN 1076-0512
- Werschler, WP. "Combining Advanced Injection Techniques: Poly-L-Lactic Acid as the Foundation for Nonsurgical Total Facial Rejuvenation and Restoration". A supplement to Cosmetic Dermatology, February 2007; Vol 20(2 S1): 9-13
- Tanghetti E, Werschler WP. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratosis on the face and scalp. Journal of Drugs in Dermatology, Feb 2007; 6(2): 144-7.
- Rendon, Marta I., MD; Sengelmann, Roberta D., MD; Weinkle, Susan, MD; and Werschler, WP. "Recognition and Treatment of Facial Lipoatrophy with Volume Restoration". Medscape. March 2006
- Werschler, WP. "Advanced Injection techniques of poly-L lactic acid: a case-based presentation". Guest Editor in Dermatologic Therapy, March 2007; Vol 20, Suppl. 1
- Werschler, WP. "Optimal Use of Facial Filling Agents: Understanding the Products". Cosmetic Dermatology, May 2007; Vol 20(5) Suppl. 2: 4-7
- Werschler, WP. Details: "Modern Skin Preparation". Medesthetics, September/October 2007: 12-14, 94.
- Rosen, Ted, MD; Gold, Michael, MD; Werschler, WP. "Chemoprevention; Its Role In Dermatology Treatments". Skin & Aging, October Supplement: 15-22
- Lupo, Mary, MD; Draelos, Zoe, MD; Farris, Patricia, MD; Mandy, Stephan, MD; McDaniel, David, MD; Taylor, Susan, MD; Werschler, WP. "CoffeeBerry: A New, Natural Antioxidant in Professional Anti-Aging Skin Care". Cosmetic Dermatology, October 2007; Vol 20(10) Sup. 4
- Larson-McMurtrey, Kari, MBA; Werschler, WP. "The Ins and Outs of a Practice Buy-in or Buy-out". Cosmetic Dermatology, October 2007; Vol 20(10): 626-629
- Werschler, WP. "Fillers, Toxins, Lasers, and More at the Annual ASCDAS meeting". Cosmetic

Dermatology, November 2006; Vol 19(11): Editorial

- Buford, Gregory A., MD, Burgess, Cheryl M., MD, Lacombe, Victor G., MD, Sherman, Richard N., MD, Vleggaar, Danny, MD, Weinkle, Susan H., MD, Werschler, WP. "The Role of Stimulatory Fillers in Aesthetic Facial Rejuvenation". *Cosmetic Dermatology*, November 2007; Vol 20(11) Suppl. 5
- Werschler, WP. "Everyone is a Winner at ASCDAS". *Cosmetic Dermatology*, November 2007; Editorial Vol 20(11): 696
- Werschler, WP. "Treating the Aging Face: A Multidisciplinary Approach with Calcium Hydroxylapatite and Other Fillers, Part 1". *Cosmetic Dermatology*, November 2007; Vol 20(11): 739-742
- Werschler, WP. "A Skin Cancer Cure?". *Family Circle*, June 2008; 137
- Del Rosso, James Q., MD, Schlessinger, Joel, MD, Werschler, WP. "Comparison of Anti-Inflammatory Dose Doxycycline versus Doxycycline 100 MG in the Treatment of Rosacea". *Journal of Drugs in Dermatology New Methods and Techniques*, June 2008; Vol 7(6): 573-6
- Werschler, WP. "The Costs of Products and Services". *Cosmetic Dermatology*, July 2008; Vol 21(7): 376-79
- Werschler, WP. "What is in a Name?". *Cosmetic Dermatology*, September 2008; Vol 21(9): 480-81 Sadick NS, Anderson D, Werschler WP. "Addressing volume loss in hand rejuvenation: a report of clinical experience". *Journal of Cosmetic Laser Therapy*. December 2008; Vol 10(4): 237-41
- Del Rosso JQ, Schlessinger J, Werschler P. "Comparison of anti-inflammatory dose doxycycline versus doxycycline 100mg in the treatment of rosacea". *Journal of Drugs in Dermatology*. December 2008; Vol 7(12): 573-576
- Werschler, WP. "Appreciation and Compassion in Times of Economic Turmoil" *Cosmetic Dermatology*, December 2008; Editorial Vol 21(12): 634-635
- Werschler, WP. "Meeting Here, Meeting There, Meeting Everywhere?" *Cosmetic Dermatology*, March 2009; Editorial Vol 22(3):116-117
- Werschler, WP. "New Developments in Topical Anesthetics" *The Journal of Clinical Aesthetic Dermatology*, April 2009; Vol 2(4): Suppl 23-25
- Hema Sundaram, MD, Rahul C. Mehta, PhD, Josie A. Norine, MA, Leon Kircik, MD, Fran E. Cook-Bolden, MD, Deborah H. Atkin, MD, W. Philip Werschler, MD, Richard E. Fitzpatrick, MD. "Topically Applied Physiologically Balanced Growth Factors: A New Paradigm of Skin Rejuvenation". *Journal of Drugs in Dermatology*, May 2009; Vol 8(5) Supplement.
- Lawrence Anderson, George J. Schmieder, W. Philip Werschler, Eduardo H. Tschen, et al. "Randomized, double-blind, double-dummy, vehicle controlled study of ingenol mebutate gel 0.25% and 0.05% for actinic keratosis." *Journal of the American Academy of Dermatology*, June 2009; Vol 60(6): 934-943
- Werschler, WP. Advances in the Use of Toxins and Fillers Presented at Maui Derm '09, Guest Editorial. *The Dermatology Report*, Spring 2009; Vol 3 (1):37
- Werschler, WP. "Hand Rejuvenation" *MedEsthetics*, Sept/Oct 2009; Vol 5(5):10-12



- Werschler, WP. "United We Stand: Combined Annual Meeting of ASDS and ASCDAS" *Cosmetic Dermatology*, October 2009; Editorial Vol 22(10): 499-500
- Richard G. Fried, MD, PHD; Wm Philip Werschler, MD; Tracy Floirendo, MA. "The Botulinum Toxin Experience – Results of a Patient Self-Report Questionnaire" *The Journal of Clinical and Aesthetic Dermatology*, November 2009; Vol 2(11):37-40
- James Q. Del Rosso, DO; Wm Philip Werschler, MD. "November Highlights" *The Journal of Clinical and Aesthetic Dermatology*, November 2009; Vol 2(11):6
- Werschler, WP; Busso, M. Prepackaged Injectable Soft-tissue Rejuvenation of the Hand and Other Nonfacial Areas. In: Alam M and Pongprutthipan M, eds. *Body Rejuvenation (Part 7)*. New York: Springer, 2010; 30:221-225.
- Rhonda S. Narins, MD, PC; Steven R. Cohen, MD, FACS. Wm Philip Werschler, MD. The Five-Year Investigator Study Group Contributor. "Novel Polymethylmethacrylate Soft Tissue Filler for the Correction of Nasolabial Folds: Interim Results of a 5-Year Long-Term Safety and Patient Satisfaction Study". *Dermatology Surgery* 2010; 36:766-774.
- Werschler, WP. et. al. "A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles." *Journal of the American Academy of Dermatology*, March 2010; Vol 62(3):448-462.
- Werschler, WP. "Thoughts on Acne and Rosacea", Guest Editorial. *Cosmetic Dermatology*, April 2010; Vol 23 (4):154
- Werschler, WP. "The Summer Meeting of the American Academy of Dermatology: Chicago", Guest Editorial. *Cosmetic Dermatology*, July 2010; Vol 23(7):299-300
- Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.; Vleggaar, Danny; Kenkel, Jeffrey M. "Introduction", *Aesthetic Surgery Journal* July/August 2010; 30:1 Suppl: 9S-10S.
- Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.; Vleggaar, Danny; Kenkel, Jeffrey M. "Nonsurgical Modalities to Treat the Aging Face", *Aesthetic Surgery Journal* July/August 2010; 30:1 Suppl: 31S-35S
- Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.; Vleggaar, Danny; Kenkel, Jeffrey M. "Update on Facial Aging", *Aesthetic Surgery Journal* July/August 2010; 30:1 Suppl: 11S-24S
- Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.; Vleggaar, Danny; Kenkel, Jeffrey M. "Facial Aesthetic Analysis", *Aesthetic Surgery Journal* July/August 2010; 30:1 Suppl: 25S-27S.
- Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.; Vleggaar, Danny; Kenkel, Jeffrey M. "Surgical Versus Nonsurgical Rejuvenation", *Aesthetic Surgery Journal* July/August 2010; 30:1 Suppl: 28S-30S.
- Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.; Vleggaar, Danny; Kenkel, Jeffrey M. "Appropriate Selection and Application of Nonsurgical Facial Rejuvenation Agents and Procedures: Panel Consensus Recommendations", *Aesthetic Surgery Journal* July/August 2010; 30:1 Suppl: 36S-45S.

- Wm. Philip Werschler, MD; Nathan S. Trookman, MD; Ronald L. Rizer, PhD; Elizabeth T. Ho, BS; and Rahul Mehta PhD. "Enhanced Efficacy of a Facial Hydrating Serum in Subjects with Normal or Self-Perceived Dry Skin." *The Journal of Clinical and Aesthetic Dermatology*, February 2011; Vol 4 (2):51-55
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses non-melanoma skin cancer, oral antibiotics, and efficacy of facial hydrating serum added to moisturizer regimen. *Journal of Clinical & Aesthetic Dermatology*. Feb 2011, Vol 4(2):10
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports published within the issue. *Journal of Clinical & Aesthetic Dermatology*. March 2011, Vol. 4(3):8
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses reports published within the issue. *Journal of Clinical & Aesthetic Dermatology*. April 2011, Vol. 4(4):12
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses reports published within the issue which include the efficacy of benzoyl peroxide gel in treating proionibacterium acnes, the factors that affect the optimal treatment of the seborrheic dermatitis, and medical lasers. *Journal of Clinical & Aesthetic Dermatology*. May 2011, Vol. 4(5):10
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports published within the issue that include the study on the performance of dermatologist in self-skin and full-body skin examinations, the prevalence on cosmetic allergens by the American Contact Alternatives Group, and a case study on the treatment of patients with skin depigmentations using excimer lasers. *Journal of Clinical & Aesthetic Dermatology*. June 2011, Vol. 4(6):12
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports with the issue on topics including the effect of body image disturbance on the quality of life of acne vulgaris patients. *Journal of Clinical & Aesthetic Dermatology*. July 2011, Vol. 4(7):12
- Brandt FS, Cazzaniga A, Baumann L, Fagien S, Glazer S, Kenkel JM, Lowe NJ, Monheit GD, Narins RS, Rendon MI, Rohrich RJ, Werschler, WP. "Investigator global evaluations of efficacy of injectable poly-L-lactic acid versus human collagen in the correction of nasolabial fold wrinkles." *Aesthetic Surgery Journal*, July 2011; 31(5)521-28
- Wm. Philip Werschler, MD: "Mirror, Mirror on the Wall, Is My Injector the Best of All?", Guest Editorial. *Cosmetic Dermatology*, July 2011; Vol 24(7):304-305
- Jo Lynne Herzog MD, James A. Solomon MD PhD, Zoe Draelos MD, Alan Fleischer Jr. MD,
- "Investigator Global Evaluations of Efficacy of Injectable Poly-L-Lactic Acid Versus Human Collagen in the Correction of Nasolabial Fold Wrinkles". William Philip Werschler, MD & others. *Aesthetic Surgery Journal*, Volume 31, Number 5, July 2011.
- "Further Enhancement of Facial Appearance with a Hydroquinone Skin Care System Plus Tretinoin in Patients previously Treated with Botulinum Toxin Type A". Philip Werschler, MD, FAAD, & others. *Aesthetic Surgery Journal*, Volume 31, Number 5, July 2011.
- Dow Stough MD, David I.Wolf MD, William Abramovits MD, William Werschler MD, Emma Green BSc, Maeve Duffy PhD, Alan Rothaul PhD, Robert Tansley MBBS. "A Randomized, Double-Blind, Vehicle-Controlled Crossover Study to Determine the Anti-Pruritic Efficacy, Safety and Local Dermal Tolerability of a Topical Formulation (SRD174 Cream) of the Long-Acting Opioid Antagonist Nalmefene in Subjects With Atopic Dermatitis." *Journal of Drugs Dermatology*. 2011 Vol.10(8):853-860

- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports published within the issue including physical modalities for acne. *Journal of Clinical & Aesthetic Dermatology*. Nov 2011, Vol. 4(11):8
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue on topics including treatment of cutaneous infections, efficacy of physiological lipid-based topical emulsion and anatomic basis for malar edema. *Journal of Clinical & Aesthetic Dermatology*. Dec 2011, Vol. 4(12):8
- Werschler, WP.; Yates, Choo. "Experts Recognize Radiesse as a True Volumizing Dermal Filler". *The Asian Aesthetic Guide*. 2012, Vol.3:2
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue on topics including the effects of sinecatechins on proteases, the photostability of a micronized formulation of tretinoin. *Journal of Clinical & Aesthetic Dermatology*. Jan 2012, Vol. 5(1):10
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue on topics including treatment of plaque psoriasis with calcitrol ointment. *Journal of Clinical & Aesthetic Dermatology*. Feb 2012, Vol. 5(2):1-10
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue on topics including managing rosacea, common clinical features of rosacea and persistent facial erythema of rosacea. *Journal of Clinical & Aesthetic Dermatology*. Mar 2012, Vol. 5(3):9
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue on topics including the incidence of nonmelanoma skin cancer and actinic keratosis, prognostic significance of follicular extension in AK, and effect of antioxidant combination in women with photoaging. *Journal of Clinical & Aesthetic Dermatology*. Mar 2012, Vol. 5(4):10
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue on topics including the tolerability of clindamycin/benzoyl peroxide gel virus, the efficacy of bluelight device in treating acne. *Journal of Clinical & Aesthetic Dermatology*. May 2012, Vol. 5(5):9
- Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses pre-treatment with forced heated air and treatment of vascular and pigmented lesions. *Journal of Clinical & Aesthetic Dermatology*. June 2012, Vol. 5(6):10
- Wm. Philip Werschler, MD: "Celebrating 25 Years", Guest Editorial. *Cosmetic Dermatology*, July 2012; Vol 25(7):297
- Wm. Philip Werschler "Oral lesions associated with injected hydroxyapatite cosmetic filler" *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, Volume 115, Issue 3, March 2013, Pages 417-419
- James J. Leyden MD, Suzanne Bruce MD, Chai Sue Lee MD, Mark Ling MD PhD, Pranav B. Sheth MD, Daniel M. Stewart DO, William P. Werschler MD, Richard D. Gilbert PhD, and Leon Kircik MD. "A Randomized, Phase 2, Dose-Ranging Study in the Treatment of Moderate to Severe Inflammatory Facial Acne Vulgaris with Doxycycline Calcium." *Journal of Drugs Dermatology*. June 2013 Vol. 12(6):658-663
- Werschler, W. P. (2013). "Who is the aesthetic consumer?" *Cutis Suppl*: 5.

- Z. Paul Lorenc, Suzanne Bruce, William Philip Werschler. "Safety and Efficacy of a Continuous-Flow, Injection-Assisted Device in Delivery of Dermal Fillers." *Aesthetic Surgery Journal*. July 2013 Vol.33(5):705-712 Karnik, J., L. Baumann, S. Bruce, V. Callender, S. Cohen, P. Grimes, J. Joseph, A. Shamban, J. Spencer, R. Tedaldi, W. P. Werschler and S. R. Smith (2014). "A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars." *J Am Acad Dermatol* 71(1): 77-83.
- Berman, B., G. Goldenberg, C. W. Hanke, S. K. Tying, W. P. Werschler, K. M. Knudsen, J. Goncalves, T. Larsson, T. Skov and N. Swanson (2014). "Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results." *J Drugs Dermatol* 13(2): 154-160.
- Berman, B., G. Goldenberg, C. W. Hanke, S. K. Tying, W. P. Werschler, K. M. Knudsen, T. Larsson and N. Swanson (2014). "Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results." *J Drugs Dermatol* 13(6): 741-747.
- "Development and Validation of a Photographic Scale for Assessment of Lip Fullness", W. Philip Werschler, & others, *Aesthetic Surgery Journal*, 2015, 35 (3): 294-307, doi: 10.1093/asj/sju025
- "Superior Efficacy of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate in an Innovative Aerosol Foam Versus Ointment, in Patients With Psoriasis Vulgaris", Authors: William Philip Werschler & others, *Clinical Poster Highlights – a supplement to Dermatology News*, Volume 46, No. 4, April 2015
- "Reaching for more RESEARCH" by Mike McLean, *Journal of Business*, Thursday May 7<sup>th</sup>, 2015, Volume 30, Issue 10, pg. 25 & 35. Dr. W. Philip Werschler, Dalyn Boehm.
- "Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies", W. Philip Werschler, MD, et. al., *JCAD*, August 2015
- "Treating Acne Scars: What's New? Consensus From the Experts", W. Philip Werschler, et. al., *Supplement to JCAD*. August 2015.
- "The Psychosocial Impact of Post-Acne Scarring", Phil Werschler, MD, et. al., *the dermatologist*, Volume 23, Issue 9. September 2015 (/issue/4816)
- "Superior Efficacy of Calcipotriene and Betamethasone Dipropionate Aerosol Foam Versus Ointment in Patients with Psoriasis Vulgaris – A Randomized Phase II Study", William P. Werschler, et. al., *Journal of Dermatological Treatment*. ISSN: 0954-6634 (Print) 1471-1753 (Online) Journal homepage: <http://www.tandfonline.com/loi/ijdt20>. October 2015
- "Aesthetic Dermatologic Treatments – Consensus From the Expert", W. Philip Werschler, et. al., *A supplement to The Journal of Clinical and Aesthetic Dermatology*. October 2015
- "Superior Efficacy of Calcipotriene and Betamethasone Dipropionate Aerosol Foam Versus Ointment in Patients with Psoriasis Vulgaris – A Randomized Phase II Study", William P. Werschler, et. al., *Journal of Dermatological Treatment*, published online: 07 Oct 2015
- "Long-term Efficacy of Micro-focused Ultrasound with Visualization for Lifting and Tightening Skin Using a Customized Vectoring Treatment Method". William Philip Werschler, MD; Pam Schell Werschler, Psy.D, ARNP, DNC

- Article Cited: “A Randomized study of the efficacy and safety of injectable Poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles” has been cited in: “Collagen Stimulators. Poly-L-Lactic Acid and Calcium Hydroxyl Apatite”. Breithaupt, A., Fitzgerald, R. Facial Plastic Surgery Clinics of North America. Volume 23, Issue 4, Year 2015, pp. 459-469.
- Article Cited: “A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars” has been cited in: “Injectable Filler Techniques for Facial Rejuvenation, Volumization, and Augmentation”. Bass, L.S. Facial Plastic Surgery Clinics of North America. Volume 23, Issue 4, Year 2015, pp. 479-488.
- Article Cited: “A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars” has been cited in: “The Case for Synthetic Injectables”. Joseph, J.H. Facial Plastic Surgery Clinics of North America. Volume 23, Issue 4, Year 2015, pp. 433-445.
- “A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study”, W. Philip Werschler, MD, et. al., American Society for Dermatologic Surgery, 42: 5S: May Supplement 2016
- “Superior Efficacy of Calcipotriene and Betamethasone Dipropionate Aerosol Foam Versus Ointment in Patients with Psoriasis Vulgaris – A Randomized Phase II Study”, William P. Werschler, et. al., Journal of Dermatological Treatment, Volume 27, 2016 – Issue 2, page 120-127, published online October 7, 2015
- Article Cited: “Photodynamic Therapy with Methyl Aminolaevulinate 80mg for Severe Facial Acne Vulgaris: A Randomized Vehicle-Controlled Study” has been cited in: “Aminolevulinate Photodynamic Therapy (ALA-PDT) for Bowen’s Disease in a SLE Patient: Case Report and Literature Review Lv, T., Zhang, J.-C., Miao, F., Wang, H.-W. Photodiagnosis and Photodynamic Therapy Volume 18, Year 2017, pp. 20-23
- “Impact of Comprehensive, Minimally Invasive, Multimodal Aesthetic Treatment on Satisfaction With Facial Appearance: The HARMONY Study”, Susan H. Weinkle, MD; W. Philip Werschler, MD; et. al., Aesthetic Surgery Journal, January 17, 2017. DOI: 10.1093/asj/sjx 179
- “Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials”, Linda Stein-Gold MD, Leon H. Kircik MD, Zoe Diana Draelos MD, Philip Werschler MD FAAD FAACS, et. al., JDD. Volume 17, Issue 11. November 2018
- “Glycopyrronium Tosylate in Pediatric Primary Axillary Hyperhidrosis: Post Hoc Analysis of Efficacy and Safety Findings by Age from Two Phase Three Randomized Controlled Trials”, Adelaide A. Hebert MD, Dee Anna Glaser MD, Lawrence Green MD, William P. Werschler MD, et. al., Pediatric Dermatology, Volume 0, Issue 0. November 19, 2018
- “Maximizing Panfacial Aesthetic Outcomes: Findings and Recommendations from the HARMONY Study”, Michael S. Kaminer, MD, Joel L. Cohen, MD, Mic A. Narurkar, MD, Ava Shamban, MD, W. Philip Werschler, MD, et. al., Dermatologic Surgery website. December 2019
- “Polymethylmethacrylate Collagen Gel-Injectable Dermal Filler for Full Face Atrophic Acne Scar Correction”, Joseph, John H. MD; Shamban, Ava MD; Eaton, Laura RN, BSN; Lehman,

Alayne RN, BSN, MS; Werschler, Phillip MD; et. al., *Dermatologic Surgery*: December 2019 – Volume 45 – Issue 12 – p 1558-1566

- “Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis”, Emil A. Tanghetti, MD, William Philip Werschler, MD, et. al., *Ortho-Derm IDP-123 Pooled Phase 3 Manuscript & Figures*. 2019
- 2020 FSDPA New Wave Dermatology Convergence. Abstract: “A Novel Tazarotene 0.045% Lotion Formulation for Moderate-To-Severe Acne: Efficacy and Safety in Phase 2 and Phase 3 Clinical Trials”. *Virtual*. 2020
- MDedge.com/Dermatology. Article (Original Research): Tolerability of Tretinoin Lotion 0.5% for Moderate-to-Severe Acne Vulgaris: A Post Hoc Analysis in a Black Population. *Cutis*. 2020 July; 106 (01): 45-50, E1. Neal D. Bhatia MD; William P. Werschler, MD, et. al. July 2020
- Fall Clinical Dermatology Conference 2020. Abstract: “Impact of Body Mass Index on Efficacy, Safety, and Tolerability of Three Topical Acne Treatments in Patients with Moderate-to-Severe Acne”. October 2020
- The Dermatology Digest: [thedermdigest.com/cosmetic\\_corner](http://thedermdigest.com/cosmetic_corner): “Regenerative Medicine: Demand in aesthetics expected to surge”. Reviewed by Wm. Philip Werschler, MD, FAAD, FAACS. February 2021
- AAD 2021. Abstract: “Impact of Body Mass Index (BMI) on Efficacy of Three Topical Acne Treatments in Patients with Moderate-to-Severe Acne”. March 2021
- Ortho Dermatologics: “Improved Spreadability of Polymeric Emulsion-Based Tazarotene Lotion Versus Trifarotene Cream for the Treatment of Acne”. July 2021
- Clinical, Cosmetic and Investigational Dermatology Journal: “Consensus on the Use of Hyaluronic Acid Fillers from the Cohesive Polydensified Matrix Range: Best Practice in Specific Facial Indications”. 2021
- Taylor Francis Online: *Journal of Dermatological Treatment*: “Efficacy and Safety of Proactive Treatment with Twice-weekly Topical Cal/BD Foam in Patients with Plaque Psoriasis Undergoing HPA-axis Testing: A PSO-LONG Subgroup Analysis”. Kim Papp, Zygmunt Adamski, Lyn Guenther, Monika Liljedahl, William Philip Werschler, et. al., Published online: 09 August 2021
- National Library of Medicine: Abstract: “Consensus on the Use of Hyaluronic Acid Fillers from the Cohesive Polydensified Matrix Range: Best Practice in Specific Facial Indications”. Published online 2021 September 8. DOI: 10.2147/CCID.S311017
- Maui Derm NP+PA Fall 2021 Abstract: “Treating Acne in Obese and Morbidly Obese Patients with Tazarotene 0.045% Lotion: Post Hoc Analysis of Pooled Phase 3 Data”. Jonette Keri, MD, PhD, Leon H Kircik, MD, Lawrence Green, MD, Glynis Ablon, MD, William Philip Werschler, MD, et. al. September/October 2021
- Dovepress.com: Expert Opinion: “Consensus on the Use of Hyaluronic Acid Fillers from the Cohesive Polydensified Matrix Range: Best Practice in Specific Facial Indications”. Van Loghem J, Sattler S, Casabona G, Werschler P, et. al. Published: 08 September 2021 Volume 2021:14 Pages 1175-1199

- National Library of Medicine: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/): “Consensus Recommendations for Optimal Augmentation of the Asian Face with Hyaluronic Acid and Calcium Hydroxylapatite Fillers”. September 2021
- National Library of Medicine: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/): “Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices”. September 2021
- Ortho Dermatologics Manuscript: “Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults with Moderate-to-Severe Acne”. February 2022
- Ortho Dermatologics Abstract: “Efficacy and Safety of Triple-Combination Clindamycin Phosphate 1.2% Benzoyl Peroxide 3.1% Adapalene 0.15% Polymeric Mesh Gel in Pediatric Participants”. Society of Pediatric Dermatology Annual Meeting 2022. July 2022

### **Electronic Media**

- Tina Alster, MD; Joseph Jorizzo, MD; Faculty: C. William Hanke, MD, MPH, FACP; Susan Weinkle, MD; Wm. Philip Werschler, MD, FAAD. CME "The Aging Face: More than Skin Deep. Release Date September 2004
- Werschler, WP and Anderson, Richard, MD. Botulinum Toxin Type A and Facial Enhancement – A practical Guide to Optimal Outcomes: An interactive, case study-based CD-ROM presenting injection training from the Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics. Jointly sponsored by Postgraduate Institute for Medicine and Health Learning Systems. Supported by an educational grant from Allergan, Inc. Release Date August 2005.
- Wm. Philip Werschler, MD, FAAD; Marta I. Rendon, MD, FAAD; Roberta D. Sengelmann, MD; Susan Weinkle, MD, FAAD. Recognition and Treatment of Facial Lipoatrophy with Volume Restoration. Supported by an independent educational grant from Dermik Aesthetics. Release Date March 2006.
- Werschler, WP, Chairman, Rendon, Marta, MD, Ditre, Cherie, MD. Facial Volume Restoration: Selecting and Applying Appropriate Treatments. Jointly sponsored by Postgraduate Institute for Medicine and EHC Communications. Supported by an educational grant from Dermik Aesthetics. Release Date April 2006.
- Werschler, WP, Monheit, Gary, MD, Donofrio, Lisa, MD. Facial Lipoatrophy and Photoaging Skin. MedsiteCME.com. Sponsored by Discovery Institute of Medical Education. Supported by Dermik Aesthetics. Live Date June 16, 2006.
- Werschler, WP, Chairman, Kinney, Brian, MD, Weinkle, Susan, MD, Lacombe, Victor, MD. Facial Restoration: Advances in Non-Surgical Treatment Options for Volume Loss. Jointly sponsored by Postgraduate Institute for Medicine and EHC Communications. Supported by an educational grant from Dermik Aesthetics. Release Date August 2006.
- Braun, Martin, MD; Weinkle, Susan, MD; Werschler, WP. Mastering the Art of Soft Tissue Fillers”. Provided through an Educational Grant from Dermik. Orlando Dermatology &

Aesthetic Conference. Orlando, Florida, 2006

- Jones, Derek H., M.D., Werschler, WP. Full Facial Rejuvenation: Portraits in Patient Satisfaction. An interactive CD-ROM presenting injection procedures. Jointly sponsored by the Elsevier Office of Continuing Medical Education and Skin Disease Education Foundation. Supported by an educational grant from Allergan, Inc. Release Date August, 2007.
- Werschler, WP. Emerging Uses of Semi-Permanent Fillers. An Educational DVD joint sponsorship of USF Health and i.e. aesthetics. Supported by an Educational Grant from BioForm Medical. Release Date: December 2008
- Mest, Douglas, MD; Werschler, WP. Profiles in Facial Rejuvenation: The Science and Art of Biostimulatory Fillers. An Interactive CD-ROM. Jointly sponsored by the Elsevier Office of Continuing Medical Education and Skin Disease Education Foundation. Supported by an educational grant from Dermik, a business unit of Sanofi-Aventis U.S. Release Date: June 2009
- Werschler, WP., July 7, 2014, Electronic brachytherapy allows collaboration between dermatologists, radiation oncologists. Dermatology Times.
- Werschler, WP., Beer, K., July 29, 2014, Verisante Technology, Inc. Welcomes Dr. Kenneth Beer and Dr. Philip Werschler onto Clinical Advisory Board. Wall Street Journal.
- Finance.yahoo.com. "Leading Aesthetic Physicans Join Neothetics' Newly Formed Corporate Advisory Board". February 12<sup>th</sup>, 2015 8:00AM
- Bellafill. "A Scar Free Me" Ask the Expert Post, Upkeep Treatment for Dermal Fillers, Dr. Philip Werschler, March 30, 2015
- Cosmetic Surgery Times Trends. Modern Medicine. "Researchers develop, validate lip-fullness scale" by Bill Gillette w/Wm. Philip Werschler. April 21, 2015. Study was published March 24<sup>th</sup> in Aesthetic Surgery Journal.
- "FDA approves ATX-101 for treatment of submental fat", Healio.com, Kybella, Perspective: Wm. Philip Werschler – Principal Investigator for the phase 3 trials of ATX-101.
- Healio.com Video "Clinical Investigator Discusses Radiesse for Hand Augmentation", June 22, 2015, William Philip Werschler MD FAAD, FAACS
- X-Medica. Online CME Program: Defining the Role of Biostimulatory, Long-Acting Soft Tissue Fillers in Facial Rejuvenation. W. Philip Werschler MD, Steven R. Cohen MD, Miles Graivier MD. July 2017
- Zestnow.com Healthy Living. Article: "Nonmelanoma Skin Cancer: Warning Signs and Treatments". (<http://zestnow.com/author/dr-wm-philip-werschler-md-faad-faacs/>) July 2017
- ADAM Intel Email Newsletter. In-Office Dispensing: Cosmeceuticals and More. William Philip Werschler. Issue: August/September 2018
- "Know The Right Tool for the Job – Discover the Right Filler for the Right Place". CME Certified Program (Video). X-Medica.rievent.com/a/29862PkyRPA. X-Medica. December 2018
- MEXS TV Expert Interview. Merz Expert Summit. Munich, Germany. November 2019



- NewBeauty Instagram Live Interview RE Covid-19. July 2020
- Prescriber's Choice KREM 2 Live Virtual Interview. December 2021
- "Dr. Werschler Endorses the SaltFacial". Saltmed.com April 2022

### **Poster Presentations**

- Werschler, WP., et. al. Patient-reported outcomes in subjects receiving botulinum toxin type A treatment for moderate to severe glabellar rhytides. 2006 AAD.
- Werschler, WP, and Tanghetti, E. Efficacy and tolerability of 5% 5-Fluorouracil cream and 5% Imiquimod cream in the management of actinic keratoses on the face and scalp. 2006 AAD.
- Werschler, WP. Evaluation of the safety and efficacy of a new superficial chemical peel. 2006 AAD.
- Carruthers, A., MD; Carruthers, J., MD; Cox, S.E., MD; Fagien, S., MD; Finn, J.C., MD; Kowalski, J., PharmD, MS; Lowe, N., MD; Ravelo, A. MPH; Stotland, M., MD; Werschler, W.P., MD. Patients' Self-Perception of Age after Botulinum Toxin Type A Treatment of Upper Facial Rhytids: Results Across Multiple Clinical Studies. 2006 Summer AAD.
- Beddingfield III, Frederick C., MD, PhD; Fagien, Steven, MD; Maas, Corey, MD; Murphy, Diane K., MBA; Thomas, Jane A., AAS,CCRA; Werschler, W, MD. Juvederm Ultra for Lip Enhancement: An Open-Label, Multicenter Study. 2009 American Society for Aesthetic Plastic Surgery.
- Schlessinger, J S, Werschler, W P, Kenkel, J. Further Enhancement of Facial Appearance with a Hydroquinone/Tretinoin Skin Care System in patients previously Treated with Botulinum Toxin Type A: A Multicenter Investigator-Masked Trial. 2009 ASDS/ASCDAS
- Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM; Larsson, T;. Field Treatment With Ingenol Mebutate Gel, 0.015%, 3 Weeks After Cryosurgery Of Actinic Keratosis Is Safe And Effective. January 2012 Winter Clinical Dermatology Conference Hawaii
- Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM; Larsson, T;. Field Treatment With Ingenol Mebutate Gel, 0.015%, 3 Weeks After Cryosurgery Of Actinic Keratosis Is Safe And Effective. January 2013 Maui Derm.
- Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM; Larsson, T;. Field Treatment With Ingenol Mebutate Gel, 0.015%, 3 Weeks After Cryosurgery Of Actinic Keratosis Is Safe And Effective. January 2013 Orlando Dermatology Aesthetic and Clinical Conference
- Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM;

Larsson, T;. Field Treatment With Ingenol Mebutate Gel, 0.015%, 3 Weeks After Cryosurgery Of Actinic Keratosis Is Safe And Effective. April 2013 Dermatology Nurses' Association 31<sup>st</sup> Annual Convention

- Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM; Larsson, T;. Field Treatment With Ingenol Mebutate Gel, 0.015%, 3 Weeks After Cryosurgery Of Actinic Keratosis Is Safe And Effective. May 2013 SOCSS
- Werschler, W; Swanson, N; Berman, B;, Goldernberg, G; Hanke, W; Tyring, S; Zografos, P; Knudsen, KM. Short-term Evaluation of Topical Treatment with Ingenol Mebutate Gel, 0.015%, 3 Weeks after Cryosurgery of Actinic Keratosis on the Face and Scalp. April 2013 South Beach Symposium
- Werschler, W; Swanson, N; Berman, B;, Goldernberg, G; Hanke, W; Tyring, S; Zografos, P; Knudsen, KM. Short-term Evaluation of Topical Treatment with Ingenol Mebutate Gel, 0.015%, 3 Weeks after Cryosurgery of Actinic Keratosis on the Face and Scalp. June 2013 Alabama Derm Summer Symposium
- Tyring, S; Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Werschler, W; Zografos, P; Knudsen, KM. Safety and efficacy of field treatment with ingenol mebutate gel after cryosurgery for actinic keratosis: comparison with phase 3 results for ingenol mebutate monotherapy. Accepted presented 2014 Summer AAD.
- E-Poster Presentation, AAD, March 21 2015, "Translational Technology for Non-Disruptive Stratum Corneum High Molecular Weight Carrier Assist", NuvesseMD, William Werschler, Dennis Condon, David Richards, Kimberly Duval.
- AAD 2016. Poster 3959: "Retrospective Safety Study of Combining Micro-focused Ultrasound with Visualization (MFU-V) with Neurotoxins and Fillers (HA and CAHA)". William P Werschler, et. al.
- AAD 2016. Poster 3978: "PMMA-Collagen for the Correction of Atrophic Acne Scars: Results of the Open Label Phase of a Randomized, Multicenter Trial with Long Term Follow-up". Wm. Philip Werschler, et. al.
- Aesthetic & Anti-aging Medicine World Congress 2016. "Substantial Improvements in Subject-Assessed Satisfaction with Appearance and Psychological Impact From Combined Facial Aesthetic Treatment With OnabotulinumtoxinA, Dermal Fillers, and Bimatoprost: Primary Results From the "Harmony" Study." W. Philip Werschler, MD, et. al.
- EADV 2016. Abstract: "DRM04 for the Treatment of Axillary Hyperhidrosis: Primary results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials". September/October 2016
- Fall Clinical 2016. Poster: "Adapalene/Benzoyl Peroxide 0.3%/2.5%: An Effective Acne Therapy Regardless of Age or Gender". Dr. Werschler, DR. Stein Gold. October 2016
- ODAC Conference 2017. Abstract: "Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for the Treatment of Facial Erythema Associated With Rosacea: Findings from 1 of 2 Pivotal Trials". January 2017
- Caribbean Dermatology Seminar 2017. Abstract: "Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for the Treatment of Facial Erythema Associated With Rosacea: Findings from 1 of 2 Pivotal Trials". January 2017

- Virgin Derm 2017 Meeting. Abstract: “Retrospective Safety Study of Combining Micro-Focused Ultrasound with Visualization (MFU-V) with Neurotoxins and Fillers (HA and CaHA). January 2017
- IMCAS 2017 Paris. Abstract: “Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects with Upper Facial Lines”. January 2017
- HDS 2017. Abstract: “Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects with Upper Facial Lines”. January 2017
- AAD 2017. Abstract: “Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects with Upper Facial Lines”. March 2017
- AAD 2017. Poster Presentation: “Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Facial Erythema Associated With Rosacea: REVEAL Study 1”. Philip Werschler, MD, FAAD, FAACS, Leon H. Kircik, et. al. March 2017
- AAD 2017. Abstract: “DRM04 for the Treatment of Primary Axillary Hyperhidrosis: Primary Results From The ATMOS-1 Phase 3 Randomized Controlled Trials”, Premier Clinical Research, Spokane, WA. March 2017
- Orlando Dermatology Aesthetic and Clinical Conference 2017. Abstract: “Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for the Treatment of Facial Erythema Associated With Rosacea: Findings from 1 of 2 Pivotal Trials”. March 2017
- MauiDerm 2017. Poster Presentation: “Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Facial Erythema Associated with Rosacea: REVEAL Study 1”. March 2017
- SCALE 2017. Poster Presentation: “Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for Treatment of Facial Erythema Associated with Rosacea: Findings from Two Pivotal Phase 3 REVEAL Studies”. May 2017
- Cosmetic Bootcamp 2017. Poster Presentation: “Maximizing Pan-facial Aesthetic Outcomes: Findings and Recommendations From the HARMONY Study”. Aspen, CO. June 2017
- DERM2017. Poster Presentation: “Glycopyrronium Tosylate (DRM04) for the Treatment of Primary Axillary Hyperhidrosis: Primary Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials”. Las Vegas, NV. July 2017
- ASDS 2017. Abstract: “Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects With Upper Facial Lines”. Chicago, IL. October 2017
- Fall Clinical 2017. Poster Presentation: “Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients With Primary Axillary Hyperhidrosis”. October 12-15, 2017
- MauiDerm 2018. 303 Poster Presentation: Aclaris A-101 Study. January 2018
- AAD 2018. Poster Presentation: “Topical Glycopyrronium Tosylate (DRM04) for the Treatment of Primary Axillary Hyperhidrosis: Pooled Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials”, David M. Pariser, Adelaide A. Hebert, Alexander Nast, William P. Werschler, et. al., February 2018
- AAD 2018. Poster Presentation: “Open-Label Study Evaluating Long-Term Safety of Topical

Glycopyrronium Tosylate (GT) in Patients With Primary Axillary Hyperhidrosis (ARIDO)".  
Dee Anna Glaser, Adelaide A. Hebert, Alexander Nast, William P. Werschler, et. al. February 2018

- AAD 2018. Poster Presentation: "Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Prior Treatment Analyses from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials", David M. Pariser, Adelaide A. Hebert, Alexander Nast, William P. Werschler, et. al. February 2018
- South Beach Symposium 2018. Abstract: "Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Prior Treatment Analyses from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials", David M. Pariser, Adelaide A. Hebert, Alexander Nast, William P. Werschler, et. al. March 2018
- South Beach Symposium 2018. Abstract: "Topical Glycopyrronium Tosylate (DRM04) for the Treatment of Primary Axillary Hyperhidrosis: Pooled Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials", David M. Pariser, Adelaide A. Hebert, Alexander Nast, William P. Werschler, et. al. March 2018
- Fall Clinical Dermatology Conference 2018. Poster Presentation: "Open-Label Study of A-101, a 40% Hydrogen Peroxide Topical Solution, in Patients With Seborrheic Keratosis", Valerie D. Callender, MD, Ellen H. Frankel, MD, Jonathan S. Weiss, MD, William P. Werschler, et.al. October 2018
- Fall Clinical Dermatology Conference 2019. Poster Presentation: "Acne-Related Quality of Life: Efficacy of a Novel Tretinoin 0.05% Lotion in Male and Female Patients with Moderate-to-Severe Disease", Sharleen St. Surn-Lord, MD, William Philip Werschler, MD, et.al. October 2019
- ODAC 2020 Annual Meeting. Poster Presentation: "Tolerability of Tretinoin 0.5% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Black/African American Population", Neal D Bhatia, MD, William P. Werschler, MD, et. al. January 2020
- 2020 Maui Derm Virtual Congress. Poster Presentation: "A New Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Efficacy and Safety in Phase 2 and Phase 3 Clinical Trials". 2020
- EADV Virtual 2020. Poster Presentation: "Proactive Treatment of Plaque Psoriasis with Twice-Weekly Topical CAL/BD Foam is Safe in Patients Undergoing HPA-AXIS Testing", Kim Papp, Zygmunt Adamski, Lyn Guenther, Monika Liljedahl, Agnieszka Miasik-Pogodzinska, Marie Holst Morch, Stephen Tyring, William Werschler, et.al. October 2020
- Maui Derm 2021. Poster Presentation: "Impact of Body Mass Index on Efficacy, Safety, and Tolerability of Once-Daily Tazarotene 0.045% Lotion in Patients with Moderate-to-Severe Acne". January 2021
- AAD VMX 2021. E-Poster Presentation: "Impact of Body Mass Index (BMI) on Efficacy of Three Topical Acne Treatments in Patients with Moderate-to-Severe Acne". April 2021
- Innovations in Dermatology 2022. Poster Presentation: "Efficacy and Safety of Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Polymeric Gel in Pediatric Participants". November 2022

## **Interviews & Feature Articles**

- Gillette, Bill. Know In-Office Retailing Pros, Cons. *Dermatology Times*, February 2005; Vol 26(2).
- Gillette, Bill. Maximize Revenue: Work Smart, Not Harder. *Dermatology Times*, March 2005; Vol 26(3): 78, 82.
- Jesitus, John. Innovations address total facial rejuvenation. *Dermatology Times*, September 2005; Vol 26 (9): 64.
- Jesitus, John. Innovations address total facial rejuvenation. *Cosmetic Surgery Times*, October 2005; Vol 8(9): 10, 17.
- Aesthetics Buyers Guide. OrthoNeutrogena's Biafine Promotes Cosmetic Wound Healing. *Clinical Roundtable Supplement*, January/February 2006; Vol 9(1): 1-8.
- Questions and Answers: ASCDAS 4th Annual Meeting. *Cosmetic Dermatology*, May 2006; Vol 19(5): 337-338.
- Gillette, Bill. U.S. Fillers Market Set To Boom, National Report. *Dermatology Times*, September 2006 Vol 27(9); Cover/48-49.
- Cosmetic Dermatology Announcement "New Associate Editor-in-Chief". *Cosmetic Dermatology*, September, 2006
- Bates, Betsy. Establish Boundaries With Cosmetics Patients. *Skin & Allergy News*, October 2006; Vol 37(10): 24
- Hilton, Lisette. Cosmetic injectables expert finds balance between practice, teaching and family. *Physician Profile*, *Dermatology Times*, October 2006; Vol 27 (10): 138-139
- Gillette, Bill. Anti-Aging; 'Manage' aging with combinations. *Dermatology Times*, January 2007; 1/78
- American Society of Cosmetic Dermatology & Aesthetic Surgery Presents ASCDAS Physician Profile. *Physician Profile*, *Cosmetic Dermatology*, March 2007; Vol 20(3): 183-184
- Gillette, Bill. Derms: The Top Pick AAD print ads aim to position specialty as go-to experts for anything skin. *Dermatology Times*, April 2007
- Physician Roundtable. Pulsating Clean – Clarisonic brush enhances treatment results. *Healthy Aging*, May/June 2007
- Kirn, Timothy. Fillers Changing Cosmetic Approach. *Skin & Allergy News*, January 2008; Vol 39(1): 19
- Jesitus, John. Combining Therapies – Offering the best treatment. *Dermatology Times*, February 2008; cover/60/62
- Integrating Dermatology and Cosmetic Dermatology Practice: An Expert Interview with William Philip Werschler, MD. *Expert Viewpoint*, *Medscape Dermatology*, November 2008
- American Society for Dermatologic Surgery 2008 Annual Meeting. Reshaping the Aging Face -Video discussion/Conference Coverage, *Medscape Dermatology*, November 2008

- Lowry, Fran. Safety, Efficacy Better With Higher-Dose Hyaluronic Acid Gel Filler. Health News Daily, December 2008; Vol 20(244)
- Lowry, Fran. Higher Dose Improves Filler's Safety, Efficacy. Aesthetic Dermatology, January 2009; 21
- Spencer, Kate. Phil Werschler, MD; Working on a national playing field while living in Spokane offers this gifted physician – and his patients – the best of both worlds. Smoke Signals, January 2009, Member Spotlight: 6-7
- Ault, Alicia. ASDS, ASCDAS Announce 2009 Joint Meeting. Skin & Allergy News, February 2009, Vol 40(2): 8
- Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebu
- SkinMedica, Vogue Interview Taiwan, September 20, 2009.
- Werschler, WP. "NouriCel-MD, key to rejuvenation" Vogue-Taiwan, October 2009; Promotion, 263
- Kristin M. Richardson, Scientific Director, MedscapeCME. Werschler, WP. "Disease and Desire": Balancing the Therapeutic and Aesthetic Needs of Patients. MedscapeCME Dermatology. Posted: 11/24/2009
- Best Doctors List 2010. Spokane Coeur d'Alene Living, March 2010; Vol 12(2):68
- Repinski, Karyn. "Prevention 3<sup>rd</sup> Annual Defy-Your-Age Beauty Awards" Prevention Magazine, October 2010; Vol 62(10):106-113
- Kevin A. Wilson, Contributing Editor. "Experts Discuss the Art of Neuromodulator Injections" The Aesthetic Guide, November/December 2010; 34-40
- Jane L. Schwanke, "AKs: What are the newest treatments for AKs?" Dermatology Times special report, May 2011
- Lisa B. Samalonis "Cosmetic competition" Dermatology Times, July 2011; Vol 32(7):42-50"
- The Wall Street Journal – RE: Verisante Technology, Inc. Welcome onto Clinical Advisory Board, Tuesday, July 29<sup>th</sup>, 2014, 10:05 a.m. ET
- "Facing the Future" – "Future Faces", INHealth, supplement to the Inlander, October-November 2014, Spokane WA.
- "Brachytherapy Breakthrough: A new option for treating skin cancer skips the scalpel", Inlander, December 1<sup>st</sup> 2014, Spokane WA
- "Embracing Aesthetics" by Laura Beliz, MedEsthetics Magazine, Volume 11, Number 3, April 2015, Featured Article & Cover
- "FDA Approves Dupixent for Atopic Dermatitis" by Andrew Blauvelt, FDA News Perspective, March 28<sup>th</sup>, 2017. Perspective Quote by Dr. William Philip Werschler.
- A4M Podcast "Regenerative Aesthetics". Chicago, IL. September 2017
- NEWBEAUTY Magazine "Experts in Your Area", Dr. Wm. Philip Werschler, Issue Winter/Spring 2018, Summer/Fall 2018 - present
- NEWBEAUTY Magazine. Blog. Skin Care – Active Ingredients. "Vitamin F is Having a

Moment and Your Skin is Going to Thank you” by Liz Ritter, Executive Editor. August 20, 2018. Dr. Werschler quoted.

- Modern Aesthetics Magazine. Article: Think Different: “I have a Lot of Friends I Could Send You” and Other Lies Patients Tell by Wendy Lewis. January/February 2019 Issue. Phil Werschler, MD, et. el.
- Dermatology Times Magazine. Article: “In-Office Dispensing Fills Care Gap”, by John Jesitus. March 2019. Wm. Philip Werschler, MD.
- 2004 – Present: Various quotes in lifestyle magazines such as Newbeauty, Life & Style, etc...

### **Lectures, Presentations & Trainings**

- Potential Profit Centers to Expand Your Cosmetic Practice, New Opportunities: ‘Private Label.’ Orlando Dermatology & Aesthetic Conference. January 2006.
- Marketing Your Practice. Orlando Dermatology & Aesthetic Conference. January 2006.
- Mastering the Art of Soft Tissue Fillers. Orlando Dermatology & Aesthetic Conference. January 2006.
- The Art & Science of Sculptra, Interactive Roundtable Discussion Group. Orlando Dermatology & Aesthetic Conference. January 2006.
- Trainer, Sculptra In-Office Training & Dinner Presentations/Phoenix. January 2006.
- Faculty Member, 3rd Annual National Education Faculty Consultant Meeting. Botox Cosmetic, MedAccess. January 2006.
- Non-surgical Total Facial Restoration. National Educators Faculty. January 2006.
- Update on Poly-L-Lactic Acid. Hawaii Dermatology Seminar. February 2006.
- New Ideas in Wound Healing – Complete Acne Treatment. Hawaii Dermatology Seminar. February 2006.
- Fillers & Faces. Advances in Cosmetic & Medical Dermatology/Hawaii. February 2006.
- Botulinum Toxin A & Fillers Live Demonstration. Advances in Cosmetic & Medical Dermatology/Hawaii. February 2006.
- Live Fillers Demonstration. Advances in Cosmetic & Medical Dermatology/Hawaii. February 2006.
- Point: Counterpoint Imiquimod vs. 5-Fluorouracil in the Treatment of Actinic Keratoses. Advances in Cosmetic & Medical Dermatology/ Hawaii. February 2006.
- Effudex Teleconference Speaker. Valeant Pharmaceuticals International and StrataMed, a division of Access Communications Incorporated. February 2006.
- Intermediate Cosmetic Surgery Course. American Academy of Dermatology Annual

Meeting/San Francisco. March 2006.

- Transitioning a Practice towards Cosmetic Dermatology. American Academy of Dermatology Annual Meeting/San Francisco. March 2006.
- The State of the Art of Aesthetic Dermatology. Live Patient Demonstrations. American Academy of Dermatology Annual Meeting/San Francisco. March 2006.
- Botox for the Upper Face: Anatomy and Treatment Considerations. Allergan Aesthetic Conference/Madrid, Spain. April 2006.
- Update on Clinical Research of Botulinum Toxins. Allergan Aesthetic Conference/ Madrid, Spain. April 2006.
- Trainer, Sculptra In-Office Training & Dinner Presentations/New York. April 2006.
- Advisor, Facial Aesthetics Advisory Board Meeting. Allergan, and Inamed, a division of Allergan. April 2006.
- Update in Cosmetic Dermatology. Presentation hosted by Clarisonic, a division of Pacific Bioscience Laboratory, Inc/Seattle. June 2006.
- A New Look, Innovations in Facial Assessment & Evaluation of Treatment Options. Jointly sponsored by Dannemiller Memorial Educational Foundation and SCIOS Continuing Education. Supported by Dermik Laboratories, a business of Sanofi-Aventis U.S./Denver. July 2006.
- Lecture: Optimizing Treatment Outcomes – Toxin & Filler. Pacific Northwest Dermatological 73rd Annual Scientific Conference, Portland Oregon. July 2006
- Faculty. Botulinum Toxin and Fillers: An Interactive, Experiential Session. American Academy of Dermatology, San Diego, CA. July 2006
- Trainer Sculptra, Advance Injection Technologies, Scottsdale, Arizona, September 2006
- Trainer Sculptra, Advance Injection Technologies, Las Vegas, Nevada, September 2006
- Trainer Sculptra, Advance Injection Techniques, San Diego, California, September 2006
- Trainer, Allergan, Aesthetic Managers Meeting; “Live demonstration of Juvederm Injection Techniques, and update on Facial Fillers.” Anaheim, California, September 2006.
- Featured Lecturer, For the Core by the Core; “Sculptra Update; Radiesse Review; Overview of the US Filler, Toxin and Aesthetic Marketplace.” San Francisco, CA, September 2006
- Guest Lecturer, International Society of Cosmetic and Laser Surgeons, “The Art of the Effective Patient Consultation” Annual Meeting, Las Vegas, NV, September, 2006
- Invited Injection Technique Instructor, Allergan National Education Faculty Meeting, Special Edition (Juvederm Launch), Laguna Beach, CA, September, 2006
- Program Conference Chair, “Advanced Aesthetic Injection Techniques”, MedAccess, Des Moines, IA, October, 2006
- Trainer, Dermik Aesthetics, “Advanced Injection Techniques for Pan-Facial Sculpting” NYC, NY, October, 2006
- Late Breaking Abstracts, “PLLA (Sculptra) Cosmetic Clinical Trial Data: Efficacy of Injectable



Poly-L-lactic Acid versus Human Collagen for the Correction of Nasolabial Fold Wrinkles”  
Palm Springs, CA, ASDS Annual Meeting, October, 2006

- All About Botox, “Treatment of the Periocular Area and Practice Pearls”, Palm Springs, CA, ASDS Annual Meeting, October, 2006
- Invited Guest Lecturer, Dermik Aesthetics, “Advanced Injection Techniques for Pan-Facial Sculpting”, Palm Springs, CA, October, 2006
- Faculty. Allergan Aesthetic Conference. Madrid, April 2006
- Clinical Reflections on Facial Aging: The Foundation for Renewal. Regional workshop series and symposium. Advances in Cosmetic and Medical Dermatology, January 2007
- Faculty. Dermik Steering Committee Meeting. Washington D.C., February 2007
- Faculty. American Academy of Dermatology 65th Annual Meeting. Washington D.C., February 2007
- Facial Aging: Review of Current Treatment Options, Patient Assessment, and Combination Usage. Advances in Cosmetic and Medical Dermatology, Hawaii, 2007
- Lecture: New Approaches to Fillers and Botulinum Toxin. ISCLS 16th International Symposium on Cosmetic Laser Surgery. Las Vegas, Nevada, September, 2007
- Faculty. Facial Aesthetic Advisory Board Meeting. Dermik. New York, November 2007
- Faculty. Juvederm Volumizing Advisory Board. Dallas, Texas, November, 2007
- Symposium Faculty. New Vistas in Facial Aesthetics. 31st Annual Hawaii Dermatology Seminar. Wailea, Maui, Hawaii, March 2008
- Faculty. Clinical Reflections on Facial Aging: The Foundation for Renewal. Regional workshop series and symposium. Las Vegas, NV, April 2007
- Faculty. Medical Aesthetics – The Art of Skin Rejuvenation; Pharmaceutical / Topical Options. The Aesthetic Show CME Scientific Program. Las Vegas, NV, May 2007.
- Program Director. The Aesthetic Show Scientific Program. Las Vegas, NV, June 2009
- Trainer/Lecture: Facial Shape and Volume – Addressing Deflationary Issues. 33<sup>rd</sup> Annual Hawaii Dermatology Seminar. Hawaii, February 2009
- Faculty. AACS 27<sup>th</sup> Annual Meeting. Phoenix, AZ Jan, 2011
- Faculty. AAD New Orleans February, 2011
- Faculty. Leo Pharma Advisory Board. Hawk Partners – Derm perspective on Physician-dispensed treatment discussion. Maui Derm, Hawaii February, 2011
- Faculty. ASCDAS. Santa Monica, CA March, 2011
- Faculty. ASDF Hawaii Derm. March, 2011
- Faculty. Merz Aesthetics Radiesse Injection Training (The Aesthetic Academy) Los Angeles, CA April, 2011
- Trainer. Scientiae, Seattle, Washington. PALETTE workshop May, 2011

- Faculty. The Aesthetic Show. Las Vegas, NV 2011
- Multi-specialty Meeting, Las Vegas, NV 2011
- Paradigm Medical. Faculty and Presentation. “Noninvasive Injectables in Facial Aesthetic Therapy”. Denver, CO 2011
- Faculty. Oregon Dermatology Society Annual Summer Meeting. Sunriver, OR
- Advisory Board, LaViv-BioCentric. New York, 2011
- Injector Trainer, Paradigm Medical. Seattle, WA 2011
- Merz Aesthetics European Expert Summit. Merz Aesthetics, Berlin 2011
- Trainer, Interactive workshops/Neurotoxins and Fillers. ASCDAS, Las Vegas 2011
- Merz Educational Grant, Paradigm Curriculum Development. Miami Beach, FL January, 2012
- Instructor, American Academy of Cosmetic Surgery, Las Vegas, January, 2012
- Faculty. 8<sup>th</sup> Annual Maui Derm. Maui, HI February, 2012
- Advisory Board, XODIAK Ad Board Meeting Merz Aesthetics. Dallas, TX February 2012
- Faculty. The Aesthetic Show. Las Vegas, NV April, 2012.
- Faculty. Multi-Specialty Meeting. Las Vegas, NV June, 2012
- Faculty. PALETTE Injection course and cannula Technique Presentation. Scientiae. Seattle, WA August, 2012
- Advisory Board Meeting. Galderma Erythema Regional Advisory Board Meeting. Washington, DC October, 2012
- Presentation, “Radiessse Volumizing Filler” MAEXS Meeting, Merz Aesthetics Amsterdam. November 2012
- Faculty/Moderator and Live Surgery Demonstration. AACS Las Vegas, NV January, 2013
- Faculty. Presentation “Fillers by Region”, “Neurotoxin and Dermal Filler Workshop”. MauiDerm, Maui, HI February, 2013
- Faculty. Scientiae PALETTE Meeting. Palo Alto, CA February, 2013
- Trainer. Scientiae PALETTE Program. Seattle, WA March, 2013
- Faculty. Scientiae PALETTE Program. Washington, DC April 2013
- Presentation. Paradigm Medical, “Innovations in Facial Aesthetic Medicine. Seattle, WA April, 2013
- Investigator Meeting. Suneva Medical, Suneva acne scar study. Los Angeles, CA April, 2013
- Faculty, presentation. The Aesthetic Show, “Advanced Neuromodulator Techniques” and “Advanced Dermal Filler Techniques.” Las Vegas, NV May, 2013
- Presentation. Paradigm Medical, “Innovations in Facial Aesthetic Medicine. Denver, CO.

June, 2013

- Faculty. Advisory Board. Lectures. ACMD, Maui, HI June, 2013
- Presentation. Paradigm Medical. Live Injections. Scottsdale, AZ July 2013
- Trainer. Galderma. Brimonidine (Rosacea). Dallas, TX August 2013
- Trainer. Scientiae PALLETTE Program. Seattle, WA September 2013
- Presentation. Paradigm Medical. Live Injections. Vancouver, WA October 2013
- Investigator Meeting. Site Solutions Summit, Amelia Island, FL October 2013
- Advisory Board Meeting, Voluma, Los Angeles, CA October 2013
- Data Safety Monitoring Board, Ulthera, October/November 2013
- Advisory Board Meeting, Merz Partners, Atlanta, GA November 2013
- Aesthetic Expert Summit, Paris, France, November 2013
- Advisory Board Meeting, PolyRemedy, Palo Alto, CA December 2013
- Investigator Meeting, Aczone, Dallas, TX December 2013
- Faculty. Live Surgery Demonstration, Moderator, Injector. American Academy of Cosmetic Surgery, Las Vegas, NV January 2014
- Faculty. Presentation “Toxin and Filler Update”, “Neuromodulator and Dermal Filler Workshop”. MauiDerm, Maui, HI January, 2014
- Advisory Board Meeting. Galderma, Maui, HI January 2014
- Advisory Board Meeting, TaroPharma, Maui, HI January 2014
- Advisory Board Meeting, Promius Pharma, Maui, HI January 2014
- Faculty. The Aesthetics Academy, San Francisco, CA February 2014
- Presentation. Paradigm Medical. Live Injections. San Francisco CA February 2014
- Faculty. American Academy of Dermatology, Denver CO March 2014
- Advisory Board Meeting. Merz, Denver CO March 2014
- Advisory Board Meeting, ARTAS, Denver CO March 2014
- Advisory Board Meeting, Sente, Denver CO, March 2014
- Speaker Program. Advanced Rad Solutions, Seattle WA March 2014
- Presentation. Paradigm Medical. Live Injections. Chicago IL April 2014
- Advisory Board. Allergan, Hollywood, CA April 2014
- Presentation. Paradigm Medical. Live Injections. Scottsdale, AZ April 2014
- Advisory Board Meeting. Nuvesse Skin Therapies, San Francisco CA April 2014
- Presentation. Paradigm Medical. Live Injections. Seattle, WA May 2014

- Presentation. Paradigm Medical. Live Injections. Denver, CO May 2014
- Advisory Board Meeting. PolyRemedy, San Francisco, May 2014
- Investigator Meeting. Suneva, Chicago IL May 2014
- Investigator Meeting. Galderma, Dallas TX May 2014
- Presentation. Paradigm Medical. Live Injections. Denver, CO May 2014
- Investigator Meeting. Suneva, Las Vegas June 2014
- Faculty. Multi-Specialty Meeting, Las Vegas NV June 2014
- Advisory Board Meeting. Nuvesse Skin Therapies, Las Vegas NV June 2014
- Presentation. Ulthera, Las Vegas NV June 2014
- Presentation. Paradigm Medical. Live Injections. Park City UT June 2014
- Faculty. NP+PA MauiDerm, Park City UT June 2014
- Faculty. The Aesthetics Show, Las Vegas, NV July 2014
- Advisory Board Meeting. Nuvesse Skin Therapies, Las Vegas NV July 2014
- Advisory Board Meeting. Merz, Las Vegas NV July 2014
- Advisory Board Meeting. Ulthera, Las Vegas NV July 2014
- Presentation. Pacific Northwest Dermatology, Seattle WA July 2014
- Advisory Board and Filming, Suneva Los Angeles CA July 2014
- Advisory Board Meeting. Belotero, San Francisco July 2014
- Advisory Board Meeting. Suneva Injection Training Workshop Filming for Acne Scars, August 2014
- Advisory Board Meeting. Suneva Board Presentation, Los Angeles, CA August 2014
- Advisory Board Meeting, Belotero, Dallas, TX August 2014
- Trainer. Scientiae PALLETTE Program. Seattle, WA September 2014
- Advisory Board Meeting. Belotero, Portland OR September 2014
- Advisory Board Meeting. Nuvesse, Castro Valley, CA September 2014
- Advisory Board Meeting. Voluma Virtual, September 2014
- Advisory Board Meeting. Restylane Silk, Galderma. Montreal, October 2014
- Educational Speaker. Celgene. Portland, OR October 2014
- CME Initiative Program. Paradigm. Chicago, IL November 2014
- Advisory Board Meeting. Belotero. Oak Brook, IL November 2014
- Advisory Board Meeting. IcadMed. San Diego, CA November 2014

- Ulthera Presentation at ASDS. Ulthera. San Diego, CA November 2014
- Educational Webinar. Paradigm. Scottsdale, AZ November 2014
- Palette Workshop. Scientiae. Seattle, WA November 2014
- THE Aesthetic Academy Presentation. THE Aesthetic Academy. Washington DC, November 2014
- Ulthera Presentation. THE Aesthetic Academy. Washington DC, November 2014
- Expert Meeting. Belotero. Bellevue, WA December 2014
- Merz NA Partners meeting. Orlando, FL December 2014
- Galderma Injector Training. Dallas, TX January 2015
- AACS 2015. Master Session: Facial Resurfacing and Skin Tightening: Micro-Focused Ultrasound. New Orleans, LA January 2015
- AACS 2015. Ultherapy Presentation: Micro-focused Ultrasound with Visualization (MFU-V) for Lifting and Tightening of Facial and Neck Skin Laxity Using a High-Density, Vectoring approach, during Session: Free paper Session on Brow, Blepharoplasty, Otoplasty and Facial Skin Tightening. New Orleans, LA January 2015
- AACS 2015. Ultherapy Presentation: Micro-focused Ultrasound with Visualization (MFU-V) for New and Exciting Uses. New Orleans, LA January 2015
- Advisory Board Meeting. MauiDerm. Maui, HI. January 2015
- MauiDerm 2015. Faculty: “Toxins: Onstage Live Patient Demonstration”. Maui, HI. January 2015
- MauiDerm 2015. Faculty: “Lunch with the Faculty: Onstage Live Patient Demonstration”. Maui, HI. January 2015
- MauiDerm 2015. Faculty: “Neuromodulator and Dermal Filler Injection Workshops-Small Group Breakout Sessions”. Maui, HI. January 2015
- Advisory Board Meeting. Sculptra. Scottsdale, AZ. February 2015
- Advisory Board Meeting. Neothetics. Miami Beach, FL. February 2015
- AbbVie Speaker Program. Humira. Bellevue, WA. John Howie Steakhouse. February 2015
- AbbVie Speaker Program. Humira. Anchorage, Ak. Fortson Dermatology & Skincare February 2015
- AbbVie Speaker Program. Humira. Anchoarge, Ak. Glacier Brewhouse. February 2015
- AbbVie Speaker Program. Humira. Anchorage, Ak. Alaska Center for Dermatology. February 2015
- Bellafill Acne Scar Training. Suneva. Las Vegas, NV. Four Seasons Hotel. February 2015
- Faculty. Paradigm. Facial Aesthetics: Advanced Techniques for Full Face Rejuvenation. Hyatt Regency Bellevue. Bellevue, WA. March 2015
- Faculty. Paradigm. Facial Aesthetics: Advanced Techniques for Full Face Rejuvenation.

The Ritz-Carlton Denver. Denver, CO. March 2015

- Advisory Board Meeting. Dermira. AAD 2015. San Francisco, CA. March 2015
- Advisory Board Meeting. Xoft. AAD 2015. San Francisco, CA. March 2015
- Investigator Meeting. B.I. AAD 2015. San Francisco, CA. March 2015
- Faculty. AAD. Course C007: Avoiding and Managing Filler Complications. AAD 2015. San Francisco, CA. March 2015
- Editorial Board Meeting. SKINmed. AAD 2015. San Francisco, CA. March 2015
- Faculty Meeting. Association of Surgical Faculty. AAD 2015. San Francisco, CA. March 2015
- AbbVie Speaker Program. Humira. Kennewick, WA. Cedars Restaurant. March 2015
- A+MD Symposium. Director. Coeur d'Alene, ID. May 2015
- A+MD. Merz Product Theatre Luncheon. "A Highly Purified Neurotoxin for your Practice" and "Refresh the Lower Face Appearance with Natural Looking Results". CDA, ID. May 2015
- A+MD. "Patient Flow: Education, Protocols and the Patient Encounter: Recipes for Success". CDA, ID. May 2015
- A+MD. "Overview of The Team: Satisfaction and Quality in the Patient Encounter". CDA, ID. May 2015
- A+MD. "MOA of Dermal Fillers and Neurotoxins: Selection, Choice and Combinations and Complications". CDA, ID. May 2015
- A+MD. "BCC/SCC Non-Surgical Advances in Treatment: Electronic Brachytherapy" CDA, ID. May 2015
- Merz Consensus Meeting: Combination of Aesthetic Interventions for Restoration and prevention of the Aging Face & Body. Presentation: Indication based interventions – same area, Lower face: Restoration & Prevention. Vancouver BC. June 2015
- Paradigm CME Meeting. Presentation: Energy-based Therapy with demonstration. Faculty. WCD. Vancouver BC. June 2015
- Clarisonic Symposium: Pollution and Advanced Cleansing Technology. Speaker. WCD. Vancouver BC. June 2015
- Paradigm Meeting: Management of Post-Acne Scarring: Advancing the Standard of Care. WCD. Vancouver BC. June 2015
- NuvesseMD Ad Board Meeting. Castro Valley, CA. June 2015
- MauiDerm NP+PA. Speaker & Injector. "Neuromodulators and Dermal Fillers: From "Beginners" to "Masters Class" Injectors – Live patient demonstrations, small group injection sessions by product. Colorado Springs, CO. June 2015
- AbbVie Presentation: "Achieving Results: Clinical Trial Experience Translated Into Clinical Practice". Chelan, WA. June 2015

- THE Aesthetic Show. Faculty. Moderator: Advanced Hands-On Procedural Training – Advanced Neuromodulator Techniques. Las Vegas, NV. July 2015
- THE Aesthetic Show. Faculty. Moderator: Advanced Hands-On Porcedural Training – Advanced Dermal Filler Techniques. Las Vegas, NV. July 2015.
- THE Aesthetic Show. Faculty. Merz Workshop: A Highly Purified Neurotoxin for Your Practice. Las Vegas, NV. July 2015
- THE Aesthetic Show. Faculty. Suneva Medical Workshop: Don't Just Live with it – Fill in Acne Scars with Bellafill. Las Vegas, NV. July 2015
- THE Aesthetic Show. Faculty. Moderator: Advanced Injectable Applications and Techniques Course. Presentation: “Optimizing Volumizers”. Las Vegas, NV. July 2015
- THE Aesthetic Show. Faculty. General Session III: Emerging Procedures and Technologies Part Two. Presentation: “Bellafill Review: Five Years of Safety Data (Sponsored By: Suneva Medical). Las Vegas, NV. July 2015
- THE Aesthetic Show. Faculty. Merz Workshop: Refresh the Lower Face Appearance with Natural Looking Results. Las Vegas, NV. July 2015
- Allergan Harmony Study Ad Board Meeting. Chicago, IL. July 2015
- Allergan Medical Aesthetics Ad Board Meeting. Chicago, IL. July 2015
- AbbVie Presentation: “TNF Inhibitor: Closing the Loop From Skin Inflammation to Structural Joint Damage”. Everett, WA. July 2015
- AbbVie Presentation: “Updated Insights in Psoriatic Diseases”. Bellevue, WA. July 2015
- AbbVie Presentation: “ TNF Inhibitors: Closing the Loop From Skin Inflammation to Structural Joint Damage”. Portland, OR. August 2015
- AbbVie Presentation: “Safety Data in Moderate to Severe Chronic Plaque Psoriasis Article Review”. Bend, OR. August 2015
- AbbVie Presentation: “TNF Inhibitors: Closing the Loop From Skin Inflammation to Structural Joint Damage”. Bend, OR. August 2015
- Revance Investigator’s Meeting. San Fransisco, CA. August 2015
- Merz. Radiesse Ad Board Meeting. New York, NY. August 2015
- Merz. Radiesse Speaker Training. New York, NY. August 2015.
- Suneva. Bellafill Acne Scar Dinner Presentation. Bellevue, WA. August 2015
- Neothetics Ad Board Meeting. Dallas, TX. September 2015
- Dermira Ad Board Meeting. Las Vegas, NV. September 2015
- Ulthera Investigator Meeting. Study ULT-146. Dallas, TX. October 2015
- Xoft Ad Board Meeting. Las Vegas, NV. September 2015
- ASDS. Cosmetic Tweets: #stikaneedleinurear. Chicago, IL. October 2015
- AbbVie Training Meeting. Rosemont, IL. October 2015

- Suneva Super PAC Speaking Event. Dr. Deb Atkin. San Diego, CA.
- Suneva Super PAC Speaking Event. Dr. Aeria Chang. San Diego, CA.
- Suneva Super PAC Speaking Event. Trulucks Seafood & Steak. San Diego, CA.
- Suneva Super PAC Injector Training. Cosmetic Surgery Institute. Phoenix, AZ.
- Suneva Super PAC Injector Training. Dr. Jeffrey J. Ptak. Scottsdale, AZ.
- Suneva Super PAC Speaking Event. Steak 44. Phoenix, AZ.
- THE Aesthetic Academy. Moderator for meeting. Newport Beach, CA. October 31- November 1, 2015
- Ulthera Presentation: Micro-Focused Ultrasound: A Novel Approach for Skin Lifting and Tightening. THE Aesthetic Academy. Newport Beach, CA. November 2015
- AbbVie Program: “A Legacy in Dermatology. A commitment to Your Patients”. Yacht Club Broiler. Silverdale, WA. November 2015
- ContinuED Medical Acne Scarring CME Expert Panel Meeting. Dallas, TX. November 2015
- Celgene Educational Program: An Oral Non-Biologic Phosphodiesterase 4 (PDE4) Inhibitor for the Treatment of Moderate to Severe Plaque Psoriasis. Gambardella’s Pasta Bella. Fairbanks, AK. November 2015
- Celgene Educational Program: An Oral Non-Biologic Phosphodiesterase 4 (PDE4) Inhibitor for the Treatment of Moderate to Severe Plaque Psoriasis. Bobby’s Downtown. Fairbanks, AK. November 2015
- Celgene Educational Program: Moderator Guide: Treating Patients with Moderate to Severe Plaque Psoriasis: A Case-Based Approach. Fortson Dermatology & Skin Center. Anchorage, AK. November 2015
- NuvesseMD Ad Board Meeting. Castro Valley, CA. December 2015
- AbbVie Presentation: “A Legacy in Dermatology. A Commitment to Your Patients.” Café Juanita. Kirkland, WA. December 2015
- Cosmetic Surgery Foundation Advisory Board Meeting. AACS. January 2016
- Merz Product Theatre: Xeomin. AACS. January 2016
- AACS Master Lecturer Presentation: Radiesse for Hands. January 2016
- AACS Ulthera Presentation: “Retrospective Study of Safety of Combining Micro-Focused Ultrasound with Visualization with Neurotoxins and Fillers”. January 2016
- AACS Board of Trustees Meeting. AACS. January 2016
- MauiDerm 2016. Maui, HI. January 2016
- Valeant Ad Board. MauiDerm. January 2016
- LEO/Picato Ad Board. MauiDerm. January 2016
- Suneva Dinner Event. Speaker. MauiDerm. January 2016



- SkinMedica Ad Board. MauiDerm. January 2016
- MauiDerm Lecture. Lunch with the Faculty Live Demonstration. January 2016
- MauiDerm Workshop. Neuromodulator & Derm Filler Injections. January 2016
- Paradigm Presentation: Acne Scarring (filmed for webinar). MauiDerm. January 2016
- Suneva. Super PAC. Bellafill training: Dr. Jeff Wheaton. Elite MD. Danville, CA. February 2016
- Suneva. Super PAC. Bellafill training: Dr. Eric Bachelor. Pleasanton, CA. February 2016
- Suneva. Super PAC. Speaking Event: Mill Steakhouse. Davnille, CA. February 2016
- Suneva. Super PAC. Bellafill Training: Dr. Emil A. Tanghetti. Sacramento, CA. February 2016
- Suneva. Super PAC. Bellafill Training & Demo: Dr. Sima Torabian & Dr. Payy Khorshidian. Sacramento, CA. February 2016
- Suneva. Super PAC. Speaking Event: Ruth's Steakhouse. Sacramento, CA. February 2016
- Radiesse Expert Program: FACE. Sullivan's Steakhouse. Anchorage, AK. February 2016
- AbbVie. Presentation: A Legacy in Dermatology. A Commitment to Your Patients. Il Granaio. Mount Vernon, WA. February 2016
- AbbVie. Presentation: A Legacy in Dermatology. A Commitment to Your Patients. North Sound Dermatology. Smokey Point, WA. February 2016
- AbbVie. Presentation: A Legacy in Dermatology. A Commitment to Your Patients. El Gaucho. Tacoma, WA. February 2016
- ContinuED Medical. Acne Scar Roundtable: An Algorithmic Strategy for Treatment CME clinical roundtable. Paradise Valley, AZ. February 2016
- Suneva. Physician Advisory Council Virtual Ad Board. February 2016
- AAD 2016. March 2016.
- SKINmed Editorial Board Meeting. AAD. March 2016
- iCAD Live Presentation 3/5/16. AAD. March 2016
- iCAD Live Presentation 3/6/16. AAD. March 2016
- Association of Surgical Faculty Meeting. AAD. March 2016
- AAD Speaker: Course C021: Avoiding and Managing Filler Complications. Cheeks, Mid-Face. AAD. March 2016
- AbbVie Presentation: A Legacy in Dermatology. A Commitment to Your Patients. BMC Dermatology. Bend, OR. March 2016

- AbbVie Presentation: A Legacy in Dermatology. A Commitment to Your Patients. Brickhouse. Bend, OR. March 2016
- ContinUED Medical Acne Scar CME Clinical Roundtable: An Algorithmic Strategy for Treatment. Newport Beach, CA. March 2016
- AbbVie Presentation: A Legacy in Dermatology. A Commitment to Your Patients. Fortson Dermatology & Skin Care. Anchorage, AK. March 2016
- AbbVie Presentation: A Legacy in Dermatology. A Commitment to Your Patients. Ginger's Restaurant. Anchorage, AK. March 2016
- Interdisciplinary Autoimmune Summit 2016. New York, NY. April 2016
- Merz. Radiesse Expert Program: Lower Face. Barbacoa. Boise, ID. April 2016
- ContinUED Medical. Acne Scar CME Roundtable: An Algorithmic Strategy for Treatment. Bellevue, WA. April 2016
- AbbVie Presentation: A Legacy in Dermatology. A Commitment to Your Patients. NW Skin Specialists. Seattle, WA. April 2016
- AbbVie Presentation: A Legacy in Dermatology. A Commitment to Your Patients. Yacht Boiler Club. Silverdale, WA. April 2016
- AbbVie Presentation: A Legacy in Dermatology. A Commitment to Your Patients. Modern Dermatology. Seattle, WA. April 2016
- Paradigm On-Demand Webinar: Advancing the Care of Post-Acne Scarring. Faculty. May 2016
- A+MD Symposium May 20-23, 2016. Chair. Coeur d'Alene Resort. Coeur d'Alene, ID. May 2016
- MauiDerm NP+PA Summer 2016. Neuromodulators and Dermal Fillers: "Master Class" Injectors. Colorado Springs, CO. June 2016
- MauiDerm NP+PA Summer 2016. Choosing the Correct Neuromodulator and Dermal Filler – Concepts and Principles of Aesthetic Injections: Part 1. Colorado Springs, CO. June 2016
- MauiDerm NP+PA Summer 2016. Aesthetic Concepts and Principles – Part 2. Colorado Springs, CO. June 2016
- MauiDerm NP+PA Summer 2016. Getting Started – Fundamental Injection Techniques for the Beginner Aesthetic Practitioner. Colorado Springs, CO. June 2016
- Allergan VOLUMA-006 Investigators Meeting. Omni Chicago Hotel. June 2016
- Dermira Hyperhidrosis Advisory Board Meeting. Hilton Chicago O'Hare Hotel. June 2016
- The Aesthetic Blueprint. Newport Beach, CA. June 2016
- THE Aesthetic Show. Moderator: Advanced Hands-On Injectable Training – Advanced Neurotoxin Techniques. Presentation: Kybella. Las Vegas, NV. July 2016

- THE Aesthetic Show. Moderator: Advanced Hands-On Injectable Training – Advanced Dermal Filler Techniques. Presentation: Radiesse for the Hands. Las Vegas, NV. July 2016
- THE Aesthetic Show. Moderator: Advanced Injectable Applications & Techniques Course. Presentation: How to Avoid Complications. Las Vegas, NV. July 2016
- THE Aesthetic Show. Presentation: Using CaHA as a Biostimulator Filler (Sponsored by Merz) Las Vegas, NV. July 2016
- THE Aesthetic Show. Presentation: Real World Experience with Kybella. Las Vegas, NV. July 2016
- CosDermIndia 2016. Allergan Round Table Meeting: Pan Facial Approach to Aesthetic Treatment. Presentation: Relevance, Efficacy & Safety (HARMONY Study), Case Study. Mumbai, India. August 2016
- CosDermIndia 2016. Allergan Harmony Podium Presentation & Panel Discussion: Anti-Aging. Mumbai, India. August 2016
- AbbVie Presentation: Weighing the Benefits and Risks of Biologics. Olympic Dermatology. Olympia, WA. September 2016
- AbbVie Presentation: Weighing the Benefits and Risks of Biologics. El Gaucho. Tacoma, WA. September 2016
- ContinuED Medical. Round Table Webinar – Host: Acne Scarring. 3<sup>rd</sup> & Sherman Medical Plaza. Spokane, WA. September 2016
- ThermiGen. CRC – Host. 3<sup>rd</sup> & Sherman Medical Plaza. Spokane, WA. September 2016
- AbbVie Presentation: Safety Data in Moderate to Severe Chronic Plaque Psoriasis Article Review. Dermatology Associates of Seattle. Seattle, WA. September 2016
- AbbVie Presentation: TNF-A and Immune Diseases: An Ongoing Story. El Gaucho. Bellevue, WA. September 2016
- AbbVie Presentation: Weighing the Benefits and Risks of Biologics. Zesta Cucina. Yakima, WA. September 2016
- AbbVie Presentation: Weighing the Benefits and Risks of Biologics. Cedars Restaurant & Lounge. Kennewick, WA. September 2016
- Muse Investigator Meeting. W Hotel Chicago. Chicago, IL. September 2016.
- Cosmetic Bootcamp 2016. Moderator: Fillers & Toxins: Dilutions and Other Details. Las Vegas, NV. October 2016.
- CBC 2016. Peel Panel w/Live Patient Demonstrations. Las Vegas, NV. October 2016
- CBC 2016. Zeltiq Presentation: Submental Shaping w/Live Patient Demo. Las Vegas, NV. October 2016
- CBC 2016. Panel: Lips & Peri-Oral Live Patient Demo. Las Vegas, NV. October 2016

- CBC 2016. Hands Live Patient Demo. Las Vegas, NV. October 2016
- CBC 2016. Presentation: Hot, Cold & Everything in Between: The Science Behind the Method. Las Vegas, NV. October 2016.
- CBC 2016. Zeltiq Presentation: Targeted Body Shaping with Cryolipolysis. Las Vegas, NV. October 2016
- Xoft Skin eBx Advisory Board Meeting. Board Member. Las Vegas, NV. October 2016
- LEO Pharma Ingenol Disoxate Medical Advisory Board Meeting. Board Member. Las Vegas, NV. October 2016
- Zeltiq. CoolSculpting Educational Workshop: A Revolutionary Approach to Non-Surgical Body Contouring. Portland, OR. November 2016
- Merz Aesthetics Partners Advisory Board Meeting. Board Member. Los Angeles, CA. November 2016
- ASDS 2016. New Orleans, LA. November 2016
- CoolSculpting Presentation: He Said, She Said: How to Turn High CoolSculpting Demand Into Practice Revenue. ASDS 2016. New Orleans, LA. November 2016.
- Merz Expert Summit 2016. Prague, Czech Republic. November 2016.
- Sanofi Ad Board. Houston, TX. December 2016
- AbbVie. Presentation: Inside & Out: The Real Impact of Psoriasis. Clunkerdagger. Spokane, WA. December 2016
- AbbVie Speaker Training. Dallas, TX. December 2016
- Merz Aesthetics Speaker Training. Dallas, TX. January 2017
- AbbVie Presentation: Truth'n Flare – Reviewing Disease Flares in Patients with Moderate to Severe Chronic Plaque Psoriasis. Office of Dr. Mark Valentine. Everett, WA. January 2017
- AbbVie Presentation: Truth'n Flare – Reviewing Disease Flares in Patients with Moderate to Severe Chronic Plaque Psoriasis. Café Juanita. Kirkland, WA. January 2017
- Suneva National Sales Meeting. Presentation during HCP Training Protocol Demo. San Diego, CA. January 2017
- AACS Annual Meeting 2017. San Diego, CA. February 2017
- Cosmetic Surgery Foundation Board Meeting. San Diego, CA. February 2017
- AACS Board Meeting. San Diego, CA. February 2017
- AACS 2017 Ulthera Presentation: Update on Dermal Filler Injection Techniques. AACS 2017. February 2017
- AbbVie Presentation: TNF-a and Immune Diseases: An Ongoing Story. Northsound Dermatology. Everett, WA. February 2017

- AbbVie Presentation: TNF-a and Immune Diseases: An Ongoing Story. Lighthouse Bar & Grill. Bellingham, WA. February 2017
- AbbVie Presentation: Weighing the Benefits and Risks of Biologics. Seattle Dermatology. Seattle, WA. February 2017
- AbbVie Presentation: Truth'n Flare – Reviewing Disease Flares in Patients with Moderate to Severe Chronic Plaque Psoriasis. Dermatology of Seattle. Seattle, WA. February 2017
- AbbVie Presentation: Truth'n Flare – Reviewing Disease Flares in Patients with Moderate to Severe Chronic Plaque Psoriasis. Mercer Island Dermatology. Mercer Island, WA. February 2017.
- AbbVie Presentation: Truth'n Flare – Reviewing Disease Flares in Patients with Moderate to Severe Chronic Plaque Psoriasis. Heartwood Provisions. Seattle, WA. February 2017
- AbbVie Presentation: TNF-a and Immune Diseases: An Ongoing Story. Madrona Dermatology. Kirkland, WA. March 2017
- AbbVie Presentation: TNF-a and Immune Diseases: An Ongoing Story. Trumpeter Public House. Mt. Vernon, WA. March 2017
- Suneva BellaDiamond Summit. San Diego, CA. March 2017
- MauiDerm 2017. Maui, HI. March 2017
- SkinMedica Ad Board. MauiDerm. Maui, HI. March 2017
- Allergan Rosacea Ad Board. MauiDerm. Maui, HI. March 2017
- MauiDerm Faculty: Neuromodulator and Dermal Filler: Onstage Live Patient Demo. Maui, HI. March 2017
- MauiDerm Faculty: Neuromodulator and Dermal Filler Injection Workshops. Maui, HI. March 2017
- Paradigm Meeting: Advances in Aesthetics: A Global Treatment Approach to Optimizing Patient Outcomes. Bellevue, WA. April 2017
- AbbVie Presentation: Learning the Links – Discussing Comorbidities Associated w/Psoriasis and Hidradenitis Suppurativa. Center for Excellence in Dermatology. Hermiston, OR. April 2017
- AbbVie Presentation: Treatment for Psoriatic Diseases: Where We Have Been and Where We Are Today. Cedars Restaurant. Kennewick, WA. April 2017
- Suneva Scientific Summit 2017. Dallas, TX. April 2017
- ASAPS (American Society for Aesthetic Plastic Surgery) Meeting 2017. San Diego, CA. April 2017
- X-Medica. Faculty. Non Surgical Face & Neck Lift: Is It for Real? San Diego Convention Center. ASAPS 2017. April 2017

- Allergan Ad Board: Advancing the Understanding and Communication of the Psychosocial Impacts of Aesthetic Treatment. Los Angeles, CA. April 2017
- Suneva Physicians Dinner. Oceanaire Seafood. San Diego, CA. April 2017
- A+MD Symposium. Chair. Coeur d'Alene Resort. Coeur d'Alene, ID. May 2017
- Thermi CAC Event. Spokane, WA. May 2017
- AbbVie Presentation: Truth 'N Flare – Reviewing Disease Flares in Patients with Moderate to Severe Chronic Plaque Psoriasis. Silver Falls Dermatology. Longview, WA. June 2017
- AbbVie Presentation: Truth 'N Flare – Reviewing Disease Flares in Patients with Moderate to Severe Chronic Plaque Psoriasis. Riverside. Hood River, OR. June 2017
- Pfizer Eucrisa Speaker Training. Dallas, TX. June 2017
- VCS 2017. Las Vegas, NV. June 2017
- Paradigm Program: Expert Strategies for Facial Rejuvenation Utilizing Longer-Acting Dermal Fillers. VCS 2017. Las Vegas, NV. June 2017
- AbbVie Presentation: TNF-a and Immune Diseases: An Ongoing Story. Alaska Center for Dermatology. Anchorage, AK. June 2017
- AbbVie Presentation: TNF-a and Immune Diseases: An Ongoing Story. Fortson Dermatology & Skincare. Anchorage, AK. June 2017
- AbbVie Presentation: Inside and Out: The Real Impact of Psoriasis. Pangea. Anchorage, AK. June 2017
- THE Aesthetic Show. Advanced Neurotoxin Techniques. Presentation: Neurotoxins: Dilutions and Other Details. July 2017
- THE Aesthetic Show. Advanced Hands-On Injectable Training. Presentation: Update on Dermal Filler Injection Techniques: Thinking Outside the Box. July 2017
- Galderma Ad Board. THE Aesthetic Show. July 2017
- THE Aesthetic Show. Advanced Injectable Applications and Techniques Course. Presentation: Anatomical Considerations in Treating the Aging Neck: Addressing Volume, Laxity, Pigmentation & Vascularity. July 2017
- Ultherapy Workshop: A Foundational Therapy for Every Aesthetic Practice. THE Aesthetic Show. July 2017
- THE Aesthetic Show. General Session: The Future of Aesthetic Dermatology. Presentation: The Emergence of Biologic Therapy in Aesthetic Medicine. July 2017
- Allergan's Botox Ad Board. San Francisco, CA. July 2017
- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. Table 13. Spokane, WA. July 2017
- Merz Aesthetics Ad Board. Merz HQ. Raleigh, NC. August 2017

- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. Broadway Medical Clinic. Portland, OR. August 2017
- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. Andina Restaurant. Portland, OR. August 2017
- Pfizer Teleconference Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. (North Bend Medical Clinic – Coos Bay, OR) Spokane, WA. August 2017
- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. Beverly’s Restaurant. Coeur d’Alene, ID. August 2017
- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. Silver Falls Dermatology. Salem, OR. September 2017
- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. Irving Street Kitchen. Portland, OR. September 2017
- A4M “The Aesthetic AntiAging Fellowship Meeting”. Presentation: Facial Sculpting Utilizing PMMA. Chicago, IL. September 2017
- A4M “The Aesthetic AntiAging Fellowship Meeting”. Live Facial Volumization Demos Parts 1 & 2. Chicago, IL. September 2017
- Suneva Scientific Summit 2017. Chicago, IL. September 2017
- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. Oregon Electric Station. Eugene, OR. September 2017
- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. Creekside Family Medicine. Medford, OR. September 2017
- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. Porters. Medford, OR. September 2017
- ASDS Annual Meeting. Chicago, IL. October 2017
- ASDS PM355: Case-based Solutions for Practice Management. Presentation: “Integrating Clinical Trials into your Dermatology Practice”. ASDS Meeting. Chicago, IL. October 2017
- ASDS CS403: Cosmetic Tweet. ASDS Meeting. Chicago, IL. October 2017
- Merz KOL Ad Board. Frankfurt, Germany. October 2017
- Pfizer Presentation: A Novel Nonsteroidal Prescription Option for Mild-to-Moderate Atopic Dermatitis. The Doctor’s Clinic. Spokane, WA. October 2017
- AbbVie Speaker Training. Dallas, TX. October 2017
- X-Medica. SutureLift Training Presentation. Seattle, WA. November 2017
- Merz Expert Summit. Montreal, QC. November 2017
- X-Medica. SutureLift Training Presentation. Denver, CO. November 2017

- AbbVie Presentation: Learning the Links - Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. West Sound Dermatology. Poulsbo, WA. January 2018
- AbbVie Presentation: Learning the Links - Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. El Gaucho. Tacoma, WA. January 2018
- AbbVie Presentation: Learning the Links - Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. Cascade Eye & Skin Center. Puyallup, WA. January 2018
- MauiDerm 2018. Maui, HI. January 2018
- MauiDerm Moderator: Dermal Filler Update 2018: What's New in Dermal Fillers and How Will We Be Using Them in 2018? Maui, HI. January 2018
- MauiDerm Panelist: What's My Treatment? How To Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling & Cosmeceuticals. Maui, HI. January 2018
- AACS Annual Meeting 2018. Las Vegas, NV. February 2018
- AACS Pre-Conference Workshop: Non-Invasive Procedures/Neuromodulators. Las Vegas Laser & Lipo. Las Vegas, NV. February 2018
- AACS Scientific Meeting. Las Vegas, NV. February 2018
- CSF Board Meeting. AACS. Las Vegas, NV. February 2018
- AACS Ulthera Presentation. Las Vegas, NV. February 2018
- X-Medica Instalift Procedure. AACS. Las Vegas, NV. February 2018
- AACS Moderator: General Session: Bringing It All Together – Panel Discussions/Case Studies. Las Vegas, NV. February 2018
- AACS Presentation: General Session: Bringing It All Together – Panel Discussions/Case Studies: Suspension Sutures & Collagen Stimulation. Las Vegas, NV. February 2018
- Dermira Investigator Meeting. Dallas, TX. February 2018
- ADAM Presentation: In-Office Dispensing: Cosmeceuticals and More. ADAM Annual Meeting 2018. San Diego, CA. February 2018
- AAD Annual Meeting 2018. San Diego, CA. February 2018
- AAD Poster Presentation: Aclaris A-101 Study. AAD Meeting. San Diego, CA. February 2018
- AbbVie Investigator Meeting. AAD 2018. San Diego, CA. February 2018
- Merz MAAC Virtual Meeting. February 2018
- AbbVie Presentation: Learning the Links – Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. Dermatology Associates. Seattle, WA. March 2018



- AbbVie Presentation: Partners in Care: Collaborating to Advance the Care for Patients with Psoriatic Arthritis. Canlis. Seattle, WA. March 2018
- AbbVie Presentation: Learning the Links – Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. Center for Excellence in Dermatology. Hermiston, OR. March 2018
- AbbVie Presentation: Learning the Links – Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. Cedars Restaurant. Kennewick, WA. March 2018
- Aclaris Virtual Speaker Training. Spokane, WA. March 2018
- AbbVie Presentation: Learning the Links – Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. The Grand Restaurant & Lounge. Spokane, WA. March 2018
- Pfizer Presentation: Spotlight on Mild-to-Moderate Atopic Dermatitis: An Update on a Steroid-Free Topical Prescription Therapy. Spencer’s Restaurant. Spokane, WA. April 2018
- Merz MAAC Ad Board. Dallas, TX. April 2018
- Pfizer Presentation: Spotlight on Mild-to-Moderate Atopic Dermatitis: An Update on a Steroid-Free Topical Prescription Therapy. Beverly’s (inside CDA Resort). Coeur d’Alene, ID. April 2018
- ASAPS 2018 Meeting. New York, NY. April 2018
- ASAPS. Cosmetic Medicine 2018. Faculty: Rejuvenation with Devices & Injectables. Marriott Marquis. New York, NY. April 2018
- ASAPS. xMedica. Suneva CME Project: Differentiating Long-Lasting Injectable Fillers: Biostimulatory vs. Replacement Agents Filming in New York. Marriott Marquis. New York, NY. April 2018
- A+MD Symposia 2018. Chair. Coeur d’Alene, ID. May 9-12, 2018
- AbbVie Presentation: Recognizing and Managing Hidradenitis Suppurativa. The Loft. Poulsbo, WA. June 2018
- AbbVie Presentation: Spectrum of Psoriasis Uncovering Real Clinical Trial Patient Success in Plaque Psoriasis. Ginger. Anchorage, AK. June 2018
- X-Medica Presentation: Know the Right Tool for the Job – Discover the Right Filler for the Right Place. VCS 2018. Las Vegas, NV. June 2018
- AbbVie Presentation: Learning the Links – Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. North Sound Dermatology. Smokey Point, WA. June 2018
- AbbVie Presentation: Learning the Links – Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. Preservation Kitchen. Bothell, WA. June 2018

- AbbVie. Pri-Med Conference Presentation: Understanding and Treating Patients with Moderate to Severe Hidradenitis Suppurativa (HS). Washington State Convention Center. Seattle, WA. June 2018
- AbbVie Presentation: Recognizing and Managing Hidradenitis Suppurativa. Grill From Impanema. CDA, ID. June 2018
- IMCAS Asia 2018. Merz Presentation: Complementary Zones to Jawline Restoration. Bangkok, Thailand. July 2018
- IMCAS Asia 2018. Merz Collaborator: Live Demo – Contoured Jawline Combination Treatment Protocol. Bangkok, Thailand. July 2018
- IMCAS Asia 2018. Merz Lecture: “The Importance of Visualization in MFU-V an Efficacy and Safety Perspective” during Merz Symposium: Understanding the Science for Optimal Outcomes. Bangkok, Thailand. July 2018
- Merz MAAC Summer Meeting – Virtual. Spokane, WA. July 2018
- GAIN “Train the Trainer” Meeting. Dallas, TX. August 2018
- AbbVie Presentation: Learning the Links – Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. High Valley Dermatology. Idaho Falls, ID. August 2018
- AbbVie WebEx Presentation: Strengthening Our Commitment to Dermatology; Evolving the Legacy. Spokane, WA. August 2018
- AbbVie Presentation: Learning the Links – Discussing Comorbidities Associated with Psoriasis and Hidradenitis Suppurativa. Comprehensive Dermatology of Idaho. Nampa, ID. August 2018
- AbbVie Presentation: Recognizing and Exploring Connections Between Select Skin Diseases & Inflammatory Bowel Disease (IBD). Chandler’s Steakhouse. Boise, ID. August 2018
- AbbVie WebEx Presentation: Strengthening Our Commitment to Dermatology; Evolving the Legacy. Spokane, WA. September 2018
- Aclaris. Eskata Presentation. Fleming’s Steakhouse. Fresno, CA. September 2018
- Merz KOL Ad Board. Frankfurt, Germany. September 2018
- Pfizer Eucrisa Speaker Training. Dallas, TX. September 2018
- Merz Extender Injection Training Workshop. Detroit, MI. October 2018
- ASDS 2018 Annual Meeting. Phoenix, AZ. October 2018
- Allergan Round Table. ASDS 2018. JW Marriott Desert Ridge. October 2018
- ASDS 2018. Faculty: ASDS 18PD400 Front Row Seat: Interactive Injectable Demos with the Masters. JW Marriott Desert Ridge. October 2018

- Cosmetic Boot Camp 2018. Faculty – Moderator, Injector, Speaker. Meritage Resort & Spa. October 2018
- AbbVie Presentation: TNF-a and Immune Diseases: An Ongoing Story. Idaho Skin Institute. Chubbuck, ID. October 2018
- Aclaris Presentation: Eskata. Tsunami Restaurant & Sushi. Salt Lake City, UT. October 2018
- Aclaris Presentation: Eskata. Swinyer-Woseth Dermatology. Salt Lake City, UT. October 2018
- Aclaris Presentation: Eskata. Provisions Restaurant. Salt Lake City, UT. October 2018
- Merz MAAC Meeting. Phoenix, AZ. October 2018
- InstaLift Procedure. Dr. Tarbet Office. Bellevue, WA. November 2018
- Aclaris. Eskata Presentation. Budd's Broiler. Richland, WA. November 2018
- Suneva Alliance Meeting. Omni La Costa Resort & Spa. San Diego, CA. November 2018
- Merz Expert Summit: Face, Body & Mind. Tivoli Hotel. Copenhagen, Denmark. November 2018
- Ulthera Video Presentation: Body Tightening – Single & Combined Interventions. Merz Expert Summit. Copenhagen, Denmark. November 2018
- Prescriber's Choice Presentation. Wild Ginger. Bellevue, WA. November 2018
- Pfizer Presentation: An Update on a Steroid-free Topical Option for Mild-to-Moderate Atopic Dermatitis in Patients 2 Years and Older. Jollymore's Dining Experience. Lewiston, ID. November 2018
- Dominion Aesthetic Technologies. Scientific Ad Board. Dominion McNair Office. Houston, TX. December 2018
- Galderma QM Phase 3 Toxin Ad Board. Grand Hyatt DFW. Dallas, TX. December 2018
- Merz. Empowering Educational Excellence Meeting. Scottsdale Marriott at McDowell Mountains. Scottsdale, AZ. January 2019
- Suneva. National Sales Meeting. The Westin Austin Downtown. Austin, TX. January 2019
- MauiDerm 2019. Lecture: Dermal Filler Update 2019: What's New in Dermal Fillers and How will We Be Using Them in 2019? Maui, HI. January 2019
- MauiDerm 2019. Lecture: Neuromodulator and Dermal Filler: Onstage Live Patient Demonstration. Maui, HI. January 2019
- MauiDerm 2019. Lecture: Neuromodulator and Dermal Filler Injection Workshops: Breakout Sessions. Maui, HI. January 2019
- Dermira Ad Board. MauiDerm. Maui, HI. January 2019

- Altreno Ad Board. MauiDerm. Maui, HI. January 2019
- Celgene Ad Board. MauiDerm. Maui, HI. January 2019
- UCB Ad Board. MauiDerm. Maui, HI. January 2019
- AAD 2019 Annual Meeting. Washington DC. February/March 2019
- Allergan Ad Board. AAD. Washington DC. February 2019
- BTL Emsculpt Presentation. AAD. Washington DC. March 2019
- Pfizer Presentation: An Update on a Steroid-Free Topical Option for Mild-to-Moderate Atopic Dermatitis in Patients 2 Years and Older. The Lodge at Columbia Point. Richland, WA. March 2019
- Suneva Ad Board. Four Seasons Resort at Las Colinas. Dallas, TX. March 2019
- Sinclair Ad Board. Convene Center. Los Angeles, CA. March 2019
- Pfizer Program: An Update on a Steroid-Free Topical Option for Mild-to-Moderate Atopic Dermatitis in Patients 2 years and Older. Arlo's Ristorante. Sandpoint, ID. March 2019
- AbbVie Presentation: Every Patient, Every Visit: A Roundtable for Looking Beyond the Skin for Patients with Psoriatic Arthritis P.S. Always Ask. Treasure Valley Dermatology & Skin Cancer Center. Boise, ID. March 2019
- AbbVie Presentation: Cross Examination: Recognizing and Exploring Connections Between Select Skin Diseases and IBD. Chandler's Steakhouse. Boise, ID. March 2019
- Merz Global Consensus Meeting. Monaco, Monte Carlo. April 2019
- Merz Presentation: New Consensus on the use of the Fillers of the Belotero CPM range "Best practice in specific facial indications". Merz Global Consensus Meeting. Fairmont Hotel. Monaco, Monte Carlo. April 2019
- Pfizer Presentation: An Update on a Steroid-Free Topical Option for Mild-to-Moderate Atopic Dermatitis in Patients 2 Years and Older. Foundry Kitchen and Cocktails. Pullman, WA. April 2019
- AbbVie Speaker Training. The Westin Denver Int'l Airport Hotel. Denver, CO. May 2019
- Sinclair Dinner Meeting. Faculty Host. El Gaucho. Bellevue, WA. May 2019
- Merz. Lift Ulthera Investigator Meeting. The Warwick Hotel. May 2019
- AbbVie Presentation: RISA Breakfast/Lunch/Dinner Programs. CT Dermatology. Fruitland, ID. June 2019
- AbbVie Presentation: Clear Conversations: Introducing SKYRIZI for Adults with Moderate to Severe Plaque Psoriasis. Twig's Bistro & Martini Bar. Boise, ID. June 2019
- X-Medica CME Workshop: Innovative Techniques with Facial Injectables. VCS. Las Vegas, NV. June 2019

- AbbVie Presentation: RISA Breakfast/Lunch/Dinner Programs. Bellevue Dermatology Clinic. Bellevue, WA. June 2019
- AbbVie Presentation: RISA Breakfast/Lunch/Dinner Programs. Water Table Restaurant. Renton, WA. June 2019
- AbbVie Presentation: Uncovering Clearance: Introducing SKYRIZI for Adults with Moderate to Severe Plaque Psoriasis. Idaho Skin Institute. Chubbuck, ID. June 2019
- AbbVie Presentation: Uncovering Clearance: Introducing SKYRIZI for Adults with Moderate to Severe Plaque Psoriasis. Bingham Memorial Dermatology. Pocatello, ID. June 2019
- Dominion SAC Meeting. Hyatt Regency DFW. Dallas, TX. June 2019
- AbbVie Presentation: Clear Commitment: Exploring Treatment Options for Your Patients. Alaska Center for Dermatology. Anchorage, AK. June 2019
- AbbVie Presentation: Clear Commitment: Exploring Treatment Options for Your Patients. Fortson Dermatology & Skin Care. Anchorage, AK. June 2019
- AbbVie Presentation: Clear Commitment: Exploring Treatment Options for Your Patients. Cache Valley Dermatology. Logan, UT. July 2019
- AbbVie Presentation: Clear Commitment: Exploring Treatment Options for Your Patients. High Valley Dermatology. Idaho Falls, ID. July 2019
- AbbVie Presentation: Clear Commitment: Exploring Treatment Options for Your Patients. Alpine Dermatology. Idaho Falls, ID. July 2019
- AbbVie Presentation: Clear Commitment: Exploring Treatment Options for Your Patients. Office of Dr. Alan Olmstead. Twin Falls, ID. July 2019
- AbbVie Presentation: Clear Commitment: Exploring Treatment Options for Your Patients. St. Luke's Dermatology. Twin Falls, ID. July 2019
- AbbVie Presentation: Clear Commitment: Exploring Treatment Options for Your Patients. Scholes Dermatology. Twin Falls, ID. July 2019
- AbbVie Presentation: Clear Commitment: Exploring Treatment Options for Your Patients. Le Coq d'Or French Restaurant. Eagle, ID. July 2019
- X-Medica CME Program: Beyond the Laser – Combination Therapy with Injectables for Optimal Outcomes. W Bellevue. Seattle, WA. September 2019
- Dermira Speaker Program: Raises the Bar. Anthony's at Columbia Point. September 2019
- AbbVie Presentation: Defining Moments: Opportunities for Identifying and Treating Hidradenitis Suppurativa in Adolescence & Beyond. Grill at Knob Hill. Ketchum, ID. October 2019
- ASDS 2019 Annual Meeting: Presentation: Session #1: What I Wish I Had Known: Navigating Contracts, the Art of Negotiation and Securing Your Dream Job. Chicago, IL. October 2019

- Paradigm Medical. Clinical Program and Live Injection Demonstration: Mastering the Use of Biostimulatory Fillers for Rejuvenating and Beautifying the Face and Body. The Westin Seattle. Seattle, WA. November 2019
- Merz Expert Summit. Lecture: “Pre-Auricular Lifting & Volumization” in the session “Soft Tissue Enhancement with Filler – Consensus Recommendations”. Munich, Germany. November 2019
- Sol-Gel Steering Committee Meeting. The Don Cesar. St. Pete Beach, FL. November 2019
- Suneva Ad Board. Omni Resort & Spa. Carlsbad, CA. December 2019
- Maui Derm 2020. Maui, HI. January 2020
- LEO Ad Board. Maui Derm. Grand Wailea. January 2020
- Amgen Ad Board. Maui Derm. Grand Wailea. January 2020
- Maui Derm Faculty: Hot Topic: Regeneration 2020 – The Science Beyond Regeneration. Grand Wailea. January 2020
- Ortho-Derm Round Table. Maui Derm. Grand Wailea. January 2020
- Castle Biosciences Ad Board. Maui Derm. Grand Wailea. January 2020
- Maui Derm Faculty: Neuromodulator and Dermal Filler Injection Workshops: Small Group Breakout Sessions. Grand Wailea. January 2020
- Allergan Ad Board: The Manufacturing and Science Behind Allergan Facial Aesthetics. Dublin & Westport, Ireland. February 2020
- Paradigm. Suneva Program: Advances in Regenerative Medicine: Best Practices to Enhance Results in Facial Rejuvenation. Irvine Marriott. Irvine, CA. February 2020
- AACS Annual Meeting 2020. Orlando, FL. February/March 2020
- AbbVie Speaker Program: Uncovering Clearance – SKYRIZI for Adults with Moderate to Severe Plaque Psoriasis. Cache Valley Dermatology. Logan, UT. March 2020
- AbbVie Speaker Program: Uncovering Clearance – SKYRIZI for Adults with Moderate to Severe Plaque Psoriasis. Idaho Skin Institute. Chubbuck, ID. March 2020
- Prescriber’s Choice: 7 Practical Steps to Survive and Thrive Through Covid-19. Webinar. Spokane, WA. April 2020
- LEO Virtual Ad Board: Ingenol Mebutate: Update on Safety and Efficacy. Spokane, WA. May 2020
- Pfizer Virtual Speaker Training. Eucrisa. Spokane, WA. May 2020
- AbbVie Virtual Speaker Program: Dermatology & Covid-19 – Navigating Patient Care Through the Pandemic. Virtual. Spokane, WA. June 2020
- AbbVie Speaker Training. Virtual. Spokane, WA. June 2020

- AbbVie PsA Ad Board. Virtual. Spokane, WA. June 2020
- Revance PrevU RHA 2&3 Injection Training. Virtual. Spokane, WA. June 2020
- AIA CEO Crisis Call. Virtual. Spokane, WA. June 2020
- Ortho Dermatologics Medical Affairs Virtual Ad Board. Spokane, WA. June 2020
- AbbVie Virtual Speaker Program 1: Studies in Clearance: SKYRIZI for Moderate to Severe Plaque Psoriasis. Spokane, WA. July 2020
- AbbVie Virtual Speaker Program 2: Studies in Clearance: SKYRIZI for Moderate to Severe Plaque Psoriasis. Spokane, WA. July 2020
- AbbVie Virtual Speaker Program 3: Studies in Clearance: SKYRIZI for Moderate to Severe Plaque Psoriasis. Spokane, WA. July 2020
- Allergan Juvederm Virtual Steering Committee Meeting. Virtual. Spokane, WA. July 2020
- AbbVie Virtual Speaker Program 4: Paving the Path Exploring a Treatment Option for Patients With Moderate to Severe Hidradenitis Suppurativa. Virtual. Spokane, WA. July 2020
- Revance PrevU RHA 4 Injection Training. Virtual. Spokane, WA. July 2020
- AbbVie Virtual Speaker Program 1: Studies in Clearance: SKYRIZI for Moderate to Severe Plaque Psoriasis. Spokane, WA. August 2020
- Merz Global KOL Pop-in Virtual Meeting. August 2020
- Sol-Gel Ad Board. Fairmont Sonoma Mission Inn & Spa. Sonoma, CA. August 2020
- AbbVie Virtual Speaker Program 2: Studies in Clearance: SKYRIZI for Moderate to Severe Plaque Psoriasis. Spokane, WA. August 2020
- AIA CEO Crisis Call. Virtual. Spokane, WA. August 2020
- Allergan Virtual Ad Board: The Precision of BOTOX Cosmetic: Explore the Impact of Dose, Dilution and Duration. Virtual. Spokane, WA. August 2020
- Allergan Dermapose KOL Experience Kick-Off Call. Spokane, WA. September 2020
- Revance Council Call. Virtual. Spokane, WA. September 2020
- AIA CEO Crisis Call. Virtual. Spokane, WA. September 2020
- AACS BOT Meeting. Virtual. Spokane, WA. September 2020
- Merz KOL Pop-In Virtual Meeting. Spokane, WA. September 2020
- AbbVie Program: Parallel Paths: Targeting Treatment Goals for Patients with Psoriatic Diseases. North Idaho Dermatology. Coeur d'Alene, ID. October 2020
- Dermapose Training. Advanced Dermatology. Lincolnshire, IL. October 2020

- Allergan Virtual Speaker Training Program: Vycross Roundtable. Spokane, WA. October 2020
- AbbVie Virtual Program: Parallel Paths: Targeting Treatment Goals for Patients with Psoriatic Diseases. Virtual. Spokane, WA. October 2020
- AbbVie Virtual Program: Studies in Clearance: SKYRIZI for Moderate to Severe Plaque Psoriasis. Virtual. Spokane, WA. October 2020
- AACS BOT Meeting. Virtual. Spokane, WA. October 2020
- AIA CEO Crisis Call. Virtual. Spokane, WA. October 2020
- Merz KOL Pop-In Virtual Meeting. Spokane, WA. November 2020
- Dominion SAC Meeting. Virtual. Spokane, WA. November 2020
- Sol-Gel Steering Committee Meeting. Fairmont Scottsdale Princess. Scottsdale, AZ. November 2020
- AbbVie Virtual Program: Seeking Clearance: Exploring SKYRIZI for Moderate to Severe Plaque Psoriasis. Virtual. Spokane, WA. January 2021
- MauiDerm 2021. Maui, HI. January 2021
- AbbVie MauiDerm Virtual Program: A Closer Look: Humira for Adult Patients. MauiDerm. Maui, HI. January 2021
- AbbVie MauiDerm Virtual Program: A Closer Look: Humira for Adult Patients. MauiDerm. Maui, HI. January 2021
- MauiDerm Lecture: Hot Topic: Regeneration Will Replace Rejuvenation 2021 – The Science Behind Regeneration. MauiDerm. Maui, HI. January 2021
- MauiDerm Faculty: What's My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium. MauiDerm. Maui, HI. January 2021
- MauiDerm Faculty: Neuromodulator and Dermal Filler: Onstage Live Patient Demo: Moderator: Neuromodulator and Dermal Filler Injection Workshops: Small-Group Breakout Sessions. MauiDerm. Maui, HI. January 2021
- AbbVie MauiDerm Virtual Product Theatre Program: Paving the Path: Exploring a Treatment Option for Patients with Moderate to Severe Hidradenitis Suppurativa. MauiDerm. Maui, HI. January 2021
- Allergan Virtual Roundtable – Speaker Training. January 2021
- Allergan Aesthetics Marketplace Advisory Panel. Virtual. January 2021
- AbbVie Dermatology Speaker Training. Virtual. February 2021



- Saudi Society of Dermatology & Dermatologic Surgery Conference: Advances in Laser and Cosmetic Dermatology. Presentation: Overview of Regenerative Aesthetic Medicine in Dermatology. Virtual. February 2021
- Suneva Commercial Ad Board. Virtual. March 2021
- Allergan Medical Institute Ad Board – panelist. March 2021
- Merz Future Leaders Program: Sourcing Info & Conducting Research. March 2021
- AIA Virtual Call: Trends in the Physician Dispensed Topicals Market. March 2021
- Allergan Botox Roundtable Ad Board (1) (Live and Recorded). March 2021
- Allergan – Next Gen Filler Meeting. Virtual. March 2021
- AIA Virtual Call: In-depth analysis of the Global Medical Aesthetic Market. April 2021
- Allergan Botox Roundtable Ad Board (2) (Live and Recorded). April 2021
- Allergan Botox Roundtable Ad Board (3) (Live and Recorded). April 2021
- Solta Clear + Brilliant Touch Ad Board. Virtual. April 2021
- Merz Future Leaders Program: Working with Societies & Faculty Positions. April 2021
- AIA Virtual Meeting. April 2021
- Allergan Botox Roundtable Ad Board (4) (Live and Recorded). April 2021
- AbbVie Virtual Program (1): HS Stories Dan: A Discussion of the Individual Journey for Patients with Moderate to Severe Hidradenitis Suppurativa. Virtual. May 2021
- AbbVie Virtual Program (2): HS Stories Dan: A Discussion of the Individual Journey for Patients with Moderate to Severe Hidradenitis Suppurativa. Virtual. May 2021
- Merz Future Leaders Program: Time Management & Choosing Opportunities. May 2021
- AbbVie Live Program: Reflections on Clearance Examination of Switching Data with SKYRIZI for Adults with Moderate to Severe Plaque Psoriasis. Snake River Dermatology. Fruitland, ID. May 2021
- AbbVie Live Program: Reflections on Clearance Examination of Switching Data with SKYRIZI for Adults with Moderate to Severe Plaque Psoriasis. Dermatology Center of Canyon County. Nampa, ID. May 2021
- AIA Virtual Meeting: Non-Invasive Body Shaping. May 2021
- AIA Virtual Meeting: CEO Forum. June 2021
- AIA Virtual Meeting: Post Pandemic Aesthetic Surge. July 2021
- CastleBio Ad Board. Churchills Steak House. Spokane, WA. August 2021
- AIA Virtual Meeting: New Ax Market Opportunities. August 2021
- Merz Master Class. San Diego, CA. September 2021

- Merz Virtual Ultherapy Ad Board. September 2021
- Suneva Virtual KOL Ad Board. September 2021
- AIA Virtual Meeting: Advances in Bodyshaping & Cellulite Treatments. Virtual. September 2021
- AIA Virtual Meeting: Facial Injectables. Virtual. October 2021
- Paradigm: Suneva: Advances in Regenerative Aesthetics: Strategies to Volumize, Lift and Renew Facial Tissues. Workshop w/Live Injections and Hands-on Training. Irvine Marriott. Irvine, CA. November 2021
- Merz Expert Summit. Virtual. November 2021
- Allergan Virtual Ad Board. December 2021
- Paradigm: Galderma: Artistry in Facial Aesthetics: Best Practices in the Use of Biostimulatory Injectables. Workshop w/Live Injections and Hands-on Training. The Ritz-Carlton Denver. Denver, CO. December 2021
- AIA Virtual Meeting: 2022 Ax Market Forecast. Virtual. December 2021
- Allergan AMI Train-the-Trainer: Infraorbital Hollows. Hotel Del Coronado. Coronado, CA. January 2022
- Maui Derm 2022. Maui, HI. January 2022
- Allergan Ad Board. Maui Derm. Grand Wailea. Maui, HI. January 2022
- Vial Ad Board. Maui Derm. Grand Wailea. Maui, HI. January 2022
- Allergan Infraorbital Hollowing Training. Maui Derm. Grand Wailea. Maui, HI. January 2022
- Maui Derm Faculty: What's My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium. Grand Wailea. Maui, HI. January 2022
- Novartis Ad Board. Maui Derm. Grand Wailea. Maui, HI. January 2022
- Maui Derm Faculty: Neuromodulator and Dermal Filler: Onstage Live Patient Demo. Grand Wailea. Maui, HI. January 2022
- Maui Derm Faculty: Neuromodulator and Dermal Filler Onstage Live Patient Demonstration: Product Specific. Grand Wailea. Maui, HI. January 2022
- Paradigm (Suneva) Meeting: Advances in Regenerative Aesthetics: Strategies to Volumize, Lift and Renew Facial Tissues. Westin South Coast Plaza. Costa Mesa, CA. February 2022
- AbbVie Speaker Training: Rinvoq. Virtual. February 2022
- AbbVie Speaker Training: Skyrizi. Virtual. February 2022
- AIA Virtual Meeting: Measuring Ax Market Performance. February 2022

- AbbVie Live Program: Reaching Beyond Skin Clearance Analyzing SKYRIZI's Skin Data for Adults with Moderate to Severe Plaque Psoriasis and Joint Data in Adults with Active Psoriatic Arthritis. CT Dermatology. Fruitland, ID. March 2022
- AbbVie Live Program: Reaching Beyond Skin Clearance Analyzing SKYRIZI's Skin Data for Adults with Moderate to Severe Plaque Psoriasis and Joint Data in Adults with Active Psoriatic Arthritis. Chateau Des Fleurs. Eagle, ID. March 2022
- AbbVie Live Program: Reaching Beyond Skin Clearance Analyzing SKYRIZI's Skin Data for Adults with Moderate to Severe Plaque Psoriasis and Joint Data in Adults with Active Psoriatic Arthritis. Gem State Dermatology. Boise, ID. March 2022
- San Diego Dermatology Symposium 2022 Annual Meeting. San Diego, Ca. March 2022
- AbbVie Live Program: Reaching Beyond Skin Clearance Analyzing SKYRIZI's Skin Data for Adults with Moderate to Severe Plaque Psoriasis and Joint Data in Adults with Active Psoriatic Arthritis. San Diego Dermatology Symposium. San Diego, CA. March 2022
- Galderma Ad Board: Medical US Rx Live Advisory Board. Grand Hyatt DFW. Dallas, TX. March 2022
- AIA Virtual Meeting: Market Innovators. March 2022
- Allergan Medical Institute: Hands-On Injection Training. Vienna Skin Clinic. San Jose, CA. April 2022
- Allergan Medical Institute: Hands-On Injection Training. California Skin Institute. Mountain View, CA. April 2022
- ASAPS Annual Meeting. San Diego Convention Center. San Diego, CA. April 2022
- ASLMS Annual Meeting. Omni Hotel. San Diego, CA. April 2022
- AIA Virtual Meeting: Rise of the Medspas. April 2022
- AbbVie Live Program: Reaching Beyond Skin Clearance Analyzing SKYRIZI's Skin Data for Adults with Moderate to Severe Plaque Psoriasis and Joint Data in Adults with Active Psoriatic Arthritis. The Scott Resort & Spa. Scottsdale, AZ. May 2022
- AbbVie Program: Clearer Horizons: Charting Long-term Results for Skyrizi in Adult Patients with Moderate-to-severe Plaque Psoriasis. Dermatology Clinic of Idaho. Boise, ID. May 2022
- AbbVie Program: Clearer Horizons: Charting Long-term Results for Skyrizi in Adult Patients with Moderate-to-severe Plaque Psoriasis. Twigs Bistro and Martini Bar. Meridian, ID. May 2022
- Allergan Medical Institute (AMI) Program: Live Hands-On Small Group Training. Leyngold Institute for Plastic Surgery. Meridian, ID. May 2022
- AMI Program: Live Hands-On Small Group Training. Rodgers Center for Plastic Surgery. Boise, ID. May 2022
- Allergan Live Roundtable. Richard's. Boise, ID. May 2022

- Allergan: The Future of Botox Ad Board. Hotel Casa del Mar. Santa Monica, CA. May 2022
- Allergan Expert Toxin Panel. Virtual. May 2022
- AIA Virtual Meeting: Generational Aesthetics. May 2022
- AMI Program: Live Hands-On Small Group Training. Silicon Valley Aesthetics Med Spa. San Jose, CA. June 2022
- AMI Program: Live Hands-On Small Group Training. Blu Cocoon Med Spa. San Jose, CA. June 2022
- Allergan Live Roundtable. Fleming's Prime Steakhouse & Wine Bar. Santa Clara, CA. June 2022
- Guest Speaker: AIA Virtual Meeting: Male Aesthetics. June 2022
- Merz Aesthetics Global KOL Advocacy Summit. JW Marriott Marquis Hotel Dubai. Dubai, UAE. July 2022
- AAD Innovation Academy 2022 Meeting. Vancouver Convention Center. Vancouver, BC. July 2022
- Speaker: AAD Innovation Academy Meeting: P037 Cosmetics. Vancouver, BC. July 2022
- AIA: Economic Impact of the Recession. Virtual. July 2022
- AbbVie LearnSkin Psoriasis Master Class Product Theater: "Beyond Traditional Plaque Psoriasis: Building Clinical Skillsets to Manage More Complex Patient Presentations". Chaired by Dr. Jason Hawkes. Presented by Dr. Werschler. Virtual. August 2022
- AbbVie Speaker Program: Challenging AD Expectations: A Therapy Option That Challenges Treatment Goals for Patients with Refractory, Moderate-to-Severe Atopic Dermatitis (AD) Who Are Not Adequately Controlled with Other Systemic Drug Products. North Sound Dermatology. Monroe, WA. September 2022
- AbbVie Speaker Program: Challenging AD Expectations: A Therapy Option That Challenges Treatment Goals for Patients with Refractory, Moderate-to-Severe Atopic Dermatitis (AD) Who Are Not Adequately Controlled with Other Systemic Drug Products. Dough Zone. Bellevue, WA. September 2022
- AbbVie Speaker Program: Challenging AD Expectations: A Therapy Option That Challenges Treatment Goals for Patients with Refractory, Moderate-to-Severe Atopic Dermatitis (AD) Who Are Not Adequately Controlled with Other Systemic Drug Products. Silver Falls Dermatology. Chehalis, WA. September 2022
- AbbVie Dinner Program: Challenging AD Expectations: A Therapy Option That Challenges Treatment Goals for Patients with Refractory, Moderate-to-Severe Atopic Dermatitis (AD) Who Are Not Adequately Controlled with Other Systemic Drug Products. Ricardo's Kitchen & Bar. Lacey, WA. September 2022
- AbbVie Speaker Program: Product Theater: Reaching Beyond Skin Clearance: Analyzing SKYRIZI's Skin Data for Adults with Moderate-to-Severe Plaque Psoriasis and Joint Data in

Adults with Active Psoriatic Arthritis. Integrative Dermatology Symposium. Loews Ventana Canyon Resort. Tucson, AZ. September 2022

- AbbVie Speaker Training. Loews O'Hare Chicago Hotel. Rosemont, IL. October 2022
- ASDS 2022 Annual Meeting. Gaylord Rockies. Denver, CO. October 2022
- LEO Ad Board: AdviseUS. Virtual. October 2022
- MJH Lifesciences Editorial Ad Board: Dermatology Times. Virtual. October 2022
- AIA Meeting: Latest Global Aesthetic Market Study. Virtual. October 2022
- Allergan Medical Institute (AMI) Speaker Training. Conrad Las Vegas at Resorts World. Las Vegas, NV. November 2022
- Revance Webinar: Daxxify. Virtual. November 2022
- Paradigm: Galderma: Body Contouring Strategies: Mastering the Art and Science of Biostimulatory Fillers. Salt Lake City Marriott City Center. Salt Lake City, UT. November 2022
- Merz Expert Summit. Vienna. November 2022
- Merz Global Leaders Kick-Off Meeting. Virtual. December 2022
- AIA Meeting: Early Stage Ax Technology Companies. Virtual. December 2022
- AMI: Virtual - Juvederm Volux XC Hands-On Deck Review w/Dr. Steve Yoelin. January 2023
- Dermtech Speaker Training. Virtual. January 2023
- Skin Cancer Lecture. Dental Study Club: Dr. David Engen DDS. Spokane, WA. January 2023
- AIA Meeting: New Dermal Fillers: The Rise of Biostimulators. Virtual. January 2023
- CastleBiosciences Scientific Advisory Meeting – DecisionDx-SCC. Dallas, TX. January 2023
- Maui Derm 2023 Annual Meeting. Maui, HI. January 2023
- Maui Derm Faculty: What's My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium. Maui, HI. January 2023
- Novartis Ad Board. Maui, HI. January 2023
- Maui Derm Faculty: Neuromodulator and Dermal Filler: On-Stage Live Patient Demonstration. Maui, HI. January 2023
- Maui Derm Faculty: Neuromodulator and Dermal Filler On-Stage Live Patient Demonstration: Product Specific. Maui, HI. January 2023
- LEO Medical Mini-Ad Board. Maui, HI. January 2023
- Merz Aesthetics Global KOL Pop-In Community Call. February 2023
- AbbVie Speaker Training – Venturing Further Deck. Virtual. February 2023

- AIA Meeting: Economic Forecast for the Global Aesthetic Industry in 2023. Virtual. February 2023
- Allergan KEYS Meeting: Knowledge and Education for Young Specialists. JW Marriott Las Vegas. Las Vegas, NV. March 2023
- AbbVie March National Webinar Series Virtual Presentation: Venturing Further PsA Long-Term Data. Virtual. March 2023
- AbbVie Presentation: Advancing Therapeutic Expectations: Examining Data to Confidently Support the RINVOQ benefit-risk discussion for Adult and Pediatric Patients with Refractory, Moderate-to-Severe Atopic Dermatitis. Puget Sound Dermatology. Edmonds, WA. March 2023
- AbbVie Dinner Presentation: Advancing Therapeutic Conversations. Fogo de Chao. Bellevue, WA. March 2023
- Allergan AMI Hands-On Injection Training – Live Small Group. Anita Elliot, Aesthetic Nurse Specialist. Walnut Creek, CA. March 2023
- Allergan AMI Hands-On Injection Training – Live Small Group. PotozkinMD Skincare & Laser Center. Walnut Creek, CA. March 2023
- Bristol Myers Squibb (BMS) Sotyktu PNW Ad Board. San Francisco Airport Marriott Waterfront. San Francisco, CA. March 2023
- AbbVie Presentation: Advancing Therapeutic Conversations. Advanced Dermatology & Skin Surgery. Spokane, WA. March 2023
- AbbVie Dinner Presentation: Advancing Therapeutic Conversations. Seasons of Coeur d’Alene. Coeur d’Alene, ID. March 2023
- AbbVie Presentation: Reaching Beyond Skin Clearance Analyzing SKYRIZI’s Skin Data for Adults with Moderate to Severe Plaque Psoriasis and Joint Data in Adults with Active Psoriatic Arthritis. Epiphany Dermatology. El Paso, TX. March 2023
- AbbVie Dinner Presentation: Reaching Beyond Skin Clearance Analyzing SKYRIZI’s Skin Data for Adults with Moderate to Severe Plaque Psoriasis and Joint Data in Adults with Active Psoriatic Arthritis. Ruth’s Steak House. El Paso, TX. March 2023

\_\_\_\_\_  
 Wm. Philip Werschler MD, FAAD, FAACS

\_\_\_\_\_  
 Date